provider: cyberian
model: deep-research
cached: false
start_time: '2026-01-15T14:49:16.386063'
end_time: '2026-01-15T15:08:06.614479'
duration_seconds: 1130.23
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: AIMP2
gene_symbol: AIMP2
uniprot_accession: Q13155
protein_description: 'RecName: Full=Aminoacyl tRNA synthase complex-interacting
multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component
p38; AltName: Full=Protein JTV-1;'
gene_info: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin.
(IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)
provider_config:
timeout: 1800
max_retries: 3
parameters:
allowed_domains: []
agent_type: claude
port: 3284
skip_permissions: true
citation_count: 16

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q13155
• Protein Description: RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1;
• Gene Information: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin. (IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "AIMP2" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'AIMP2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene AIMP2 (gene ID: AIMP2, UniProt: Q13155) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

AIMP2: A Multifunctional Scaffold Protein Linking Translation to Cell Fate Determination

Introduction

Aminoacyl-tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2), also known as p38 or JTV-1, is a non-enzymatic component of the multi-aminoacyl-tRNA synthetase complex (MSC) in mammalian cells. Originally identified as a structural scaffold essential for MSC assembly [kim-2002-p38-scaffold-abstract], AIMP2 has emerged as a multifunctional protein that participates in diverse cellular processes beyond its canonical role in translation. The 312-amino acid protein encoded by the human AIMP2 gene (chromosome 7p22.1, UniProt Q13155) contains a glutathione S-transferase (GST)-like domain at its C-terminus and an N-terminal region that mediates interactions with lysyl-tRNA synthetase [zhou-2020-AIMPs-cancer-review]. Through its capacity to dissociate from the MSC and translocate to the nucleus upon various cellular stresses, AIMP2 functions as a critical mediator linking the translational machinery to tumor suppression, apoptosis, and cellular differentiation. This review synthesizes current knowledge of AIMP2 structure, function, subcellular dynamics, and roles in disease pathogenesis.

Gene Discovery and Nomenclature

The AIMP2 gene was first discovered in 1995 by Nicolaides, Kinzler, and Vogelstein during their characterization of the PMS2 mismatch repair gene and its promoter region [nicolaides-1995-JTV1-discovery-abstract]. They identified a novel overlapping gene, which they designated JTV1, transcribed from the opposite strand in a head-to-head arrangement with PMS2, separated by approximately 200 base pairs [nicolaides-1995-JTV1-discovery-abstract]. JTV1 was found to be ubiquitously expressed and encode a predicted 312-amino acid protein with limited sequence identity to glutathione S-transferases [nicolaides-1995-JTV1-discovery-abstract]. The gene was mapped to chromosome 7p22 by virtue of the fluorescence in situ hybridization mapping of the adjacent PMS2 gene.

The functional connection to the multi-tRNA synthetase complex was established later when Quevillon et al. (1999) identified p38 as a non-synthetase component of the macromolecular aminoacyl-tRNA synthetase complex, recognizing it as the same protein as JTV1. By examination of genomic sequences, they showed that p38 has no homolog in yeast, bacteria, or archaea, indicating it is an evolutionary innovation of higher eukaryotes [park-2010-AIMPs-review-abstract]. The current approved gene symbol AIMP2 (Aminoacyl tRNA synthetase complex-Interacting Multifunctional Protein 2) reflects the protein's function as one of three auxiliary factors in the MSC, alongside AIMP1/p43 and AIMP3/p18.

Domain Architecture and Protein Structure

AIMP2 is organized into three distinct functional domains that mediate its diverse interactions within the MSC and in signaling pathways. Computational domain analysis by InterPro and Pfam has identified the following regions: the AIMP2-LysRS binding domain (residues 1-44), a thioredoxin-like domain (residues 118-208), and the C-terminal GST domain (residues 235-309) [zhou-2020-AIMPs-cancer-review]. Analysis of deleterious missense mutations in AIMP2 found that 18 of 24 pathogenic variants localized to these three functional domains, underscoring their importance for protein function.

The N-terminal AIMP2-LysRS binding domain mediates the critical interaction with lysyl-tRNA synthetase (LysRS/KRS). X-ray crystallography of the human LysRS-AIMP2 complex (PDB 4DPG) at 2.84 angstrom resolution revealed that two AIMP2 N-terminal peptides form an antiparallel scaffold that holds two LysRS dimers through four binding motifs and additional interactions [fang-2013-LysRS-AIMP2-structure-abstract]. Importantly, all four catalytic subunits of LysRS in the assembled complex remain accessible for tRNA recognition, indicating that the scaffolding function does not impede enzymatic activity [fang-2013-LysRS-AIMP2-structure-abstract]. Two human disease-associated mutations in LysRS have been shown to conflict with this assembly, causing LysRS release from the MSC and enzyme inactivation [fang-2013-LysRS-AIMP2-structure-abstract].

The C-terminal GST-homology domain of AIMP2 participates in a heterotetrameric complex with GST-homology domains from glutamyl-prolyl-tRNA synthetase (EPRS), AIMP3, and methionyl-tRNA synthetase (MRS), arranged in the order MRS-AIMP3-EPRS-AIMP2 [hahn-2019-DRS-AIMP2-structure-abstract]. X-ray crystallography of the DRS-AIMP2-EPRS ternary subcomplex (PDB 6IY6) at 3.6 angstrom resolution established that AIMP2 interacts with EPRS primarily through heterodimerization of their respective GST domains, while aspartyl-tRNA synthetase (DRS) binds to AIMP2 through hydrogen bonds between the alpha7-beta9 loop of DRS and the beta2-alpha2 loop of AIMP2-GST [hahn-2019-DRS-AIMP2-structure-abstract]. The residue Ser156 of AIMP2 is critical for this interaction, with the side chain acting as a hydrogen-bond donor coupled with the backbone amide group of Phe339 of DRS. This DRS-centered subcomplex functions as an architectural pivot connecting two AIMP2-centered subcomplexes to assemble the complete ~1.5 MDa MSC [hahn-2019-DRS-AIMP2-structure-abstract].

The Multi-tRNA Synthetase Complex

The mammalian MSC is a macromolecular assembly comprising eight aminoacyl-tRNA synthetases (ARSs)—including those for arginine (RRS), aspartate (DRS), glutamine (QRS), isoleucine (IRS), leucine (LRS), lysine (KRS), methionine (MRS), and the bifunctional glutamyl-prolyl enzyme (EPRS)—together with three non-enzymatic auxiliary proteins: AIMP1/p43, AIMP2/p38, and AIMP3/p18 [zhou-2020-AIMPs-cancer-review][park-2010-AIMPs-review-abstract]. Within this complex, AIMP2 serves as a central scaffold that organizes the component enzymes into distinct subcomplexes. Among the three AIMPs, AIMP2 interacts with the majority of component proteins, making it essential for overall complex integrity [park-2010-AIMPs-review-abstract].

Structural studies have revealed that AIMP2 contains two functionally distinct regions that distribute MSC components into separate subcomplexes. The N-terminal region of AIMP2 binds the homodimeric interface of lysyl-tRNA synthetase (KRS), while also associating with arginyl-tRNA synthetase (RRS), glutaminyl-tRNA synthetase (QRS), and AIMP1 [zhou-2020-AIMPs-cancer-review]. The three AIMPs are tightly linked with each other and their cellular stabilities appear to be interdependent; immunogold electron microscopy localized AIMP1 at the center of the multi-tRNA synthetase complex [park-2010-AIMPs-review-abstract].

The essential nature of AIMP2's scaffolding function was demonstrated through gene disruption studies in mice. Homozygous p38-null mice showed complete disintegration of the MSC, with severely decreased protein levels and catalytic activities of component enzymes [kim-2002-p38-scaffold-abstract]. These mice were born alive but exhibited neonatal lethality within two days of birth, underscoring the physiological importance of an intact MSC for mammalian survival [kim-2002-p38-scaffold-abstract].

Subcellular Localization and Stress-Induced Dynamics

Under basal conditions, AIMP2 resides primarily in the cytoplasm as an integral component of the MSC. However, upon exposure to various cellular stresses—including DNA damage, TGF-beta signaling, and TNF-alpha stimulation—AIMP2 undergoes post-translational modification, dissociates from the MSC, and translocates to the nucleus to execute non-translational functions [han-2008-p53-genotoxic-abstract][kim-2003-lung-differentiation-abstract].

The mechanism of AIMP2 nuclear translocation has been extensively characterized in the context of genotoxic stress. Upon UV irradiation or DNA damage, AIMP2 is rapidly phosphorylated by c-Jun N-terminal kinase (JNK) [han-2008-p53-genotoxic-abstract]. This phosphorylation triggers dissociation of AIMP2 from the MSC, as demonstrated by experiments showing that JNK inhibitor II blocked both the generation of dissociated AIMP2 and its nuclear accumulation following UV exposure [han-2008-p53-genotoxic-abstract]. Nuclear translocation of AIMP2 occurs within 3-10 minutes of UV exposure, consistent with a rapid-response mechanism linking the translational machinery to the DNA damage response [han-2008-p53-genotoxic-abstract].

Similarly, TGF-beta stimulation induces phosphorylation of AIMP2 at Ser156 by p38 MAPK (note: this is the MAP kinase p38, distinct from the AIMP2 protein also historically called p38), promoting its dissociation from the MSC and nuclear translocation [kim-2016-smurf2-cancer-abstract]. The crystal structure of the S156D phosphomimetic mutant demonstrated that phosphorylation at this residue disrupts the DRS-AIMP2 interface, providing a structural explanation for how stress-induced phosphorylation releases AIMP2 from the MSC [hahn-2019-DRS-AIMP2-structure-abstract].

The structural basis for LysRS release from the MSC has also been elucidated. Phosphorylation of LysRS at Ser207 provokes a conformational change that creates steric clashes at the LysRS domain interface, disrupting its binding grooves for AIMP2 [fang-2013-LysRS-AIMP2-structure-abstract]. This releases LysRS and triggers its nuclear translocation, where it binds to the transcription factor MITF and produces the second messenger Ap4A that activates MITF-dependent gene expression [fang-2013-LysRS-AIMP2-structure-abstract]. Thus, phosphorylation serves as a general mechanism for releasing MSC components for non-translational functions.

Tumor Suppressor Functions and Signaling Pathways

AIMP2 functions as a potent tumor suppressor through multiple independent mechanisms, and has been characterized as a haploinsufficient tumor suppressor—meaning that loss of even one allele compromises its protective function [zhou-2020-AIMPs-cancer-review]. Heterozygous AIMP2 mice showed enhanced susceptibility to tumor formation in lung, colon, and skin carcinogenesis models [choi-2011-AIMP2-DX2-cancer-abstract].

The p53 Pathway

Upon DNA damage, nuclear AIMP2 directly interacts with the tumor suppressor p53, specifically binding to its N-terminal transactivation domain (amino acids 1-32) [han-2008-p53-genotoxic-abstract]. This interaction competitively blocks the access of MDM2, the E3 ubiquitin ligase responsible for p53 degradation, thereby preventing MDM2-mediated ubiquitination and stabilizing p53. AIMP2-deficient cells exhibited approximately three-fold less apoptosis following UV irradiation compared to wild-type cells, demonstrating the functional importance of this pathway [han-2008-p53-genotoxic-abstract]. Notably, AIMP2 mutations identified in lung cancer cell lines (I92V, G209S, E97D/P98L/T99S) abolished p53 activation capability, suggesting that loss of AIMP2 function contributes to carcinogenesis [han-2008-p53-genotoxic-abstract]. The clinical relevance of this pathway was further supported by experiments showing that Nutlin-3, a small molecule that inhibits the MDM2-p53 interaction, could recover p53 levels and UV-induced apoptotic sensitivity in AIMP2-deficient cells [han-2008-p53-genotoxic-abstract].

The TGF-beta/FBP/c-Myc Pathway

AIMP2 mediates TGF-beta-induced growth arrest through regulation of the oncoprotein c-Myc. Nuclear AIMP2 binds to FUSE-binding protein (FBP), a transcriptional activator of c-myc, and promotes its ubiquitin-dependent degradation [kim-2003-lung-differentiation-abstract]. This process involves AIMP2 interaction with Smurf2, an E3 ubiquitin ligase, which enhances FBP ubiquitination and subsequent proteasomal degradation [kim-2016-smurf2-cancer-abstract]. The resulting downregulation of c-Myc is essential for cellular differentiation, as demonstrated by the lung differentiation defects and respiratory distress syndrome observed in p38-deficient mice [kim-2003-lung-differentiation-abstract]. These mice showed elevated FBP and c-Myc levels in fetal lungs, leading to uncontrolled proliferation of lung epithelial cells and failure to differentiate into functional alveolar type II cells [kim-2003-lung-differentiation-abstract].

The Wnt/beta-Catenin Pathway

In intestinal epithelium, AIMP2 suppresses Wnt/beta-catenin signaling by disrupting the interaction between AXIN and Dishevelled-1 (DVL1) through competitive binding [yum-2016-Wnt-intestine-abstract]. AIMP2 is highly expressed in intestinal crypts, and hemizygous deletion of Aimp2 led to expansion of intestinal stem cells and Paneth cells, accompanied by increased expression of Wnt target genes [yum-2016-Wnt-intestine-abstract]. In the ApcMin/+ mouse model of intestinal tumorigenesis, hemizygous Aimp2 deletion enhanced intestinal adenoma formation, further establishing AIMP2 as a haploinsufficient tumor suppressor that fine-tunes Wnt signaling to regulate stem cell populations [yum-2016-Wnt-intestine-abstract].

The TNF-alpha/TRAF2 Pathway

AIMP2 promotes TNF-alpha-induced apoptosis by facilitating the degradation of TRAF2, an adapter protein that mediates anti-apoptotic NF-kappaB signaling [choi-2009-TNF-TRAF2-abstract]. AIMP2 binds to TRAF2 and augments its association with c-IAP1, an E3 ubiquitin ligase, promoting ubiquitin-dependent TRAF2 degradation [choi-2009-TNF-TRAF2-abstract]. TNF-alpha-induced cell death was compromised in AIMP2-deficient or -suppressed cells, while exogenous AIMP2 supplementation enhanced apoptotic sensitivity [choi-2009-TNF-TRAF2-abstract].

Regulation of RNA Editing via ADAR Proteins

Beyond its canonical functions, AIMP2 has been identified as a negative regulator of adenosine-to-inosine (A-to-I) RNA editing through its effects on ADAR protein stability [tan-2017-RNA-editing-ADAR-abstract]. A comprehensive analysis of the RNA editing landscape across human tissues using GTEx data revealed AIMP2 as a key factor controlling editing levels in muscle tissue [tan-2017-RNA-editing-ADAR-abstract].

Western blot analysis demonstrated that overexpression of AIMP2 in MCF7 cells reduced the protein levels of both the p150 and p110 isoforms of ADAR1 [tan-2017-RNA-editing-ADAR-abstract]. Cycloheximide chase experiments confirmed that AIMP2 promotes degradation of the editing enzymes: when protein synthesis was inhibited, levels of ADAR1 protein decreased more rapidly in AIMP2-overexpressing cells than in controls [tan-2017-RNA-editing-ADAR-abstract]. AIMP2 negatively impacts the stability of both ADAR1 and ADAR2, consistent with its previously characterized non-canonical function in regulating protein stability [tan-2017-RNA-editing-ADAR-abstract].

This function has tissue-specific implications: AIMP2 expression is highest in skeletal muscle, which displays the lowest RNA editing levels among profiled tissues [tan-2017-RNA-editing-ADAR-abstract]. Statistical analysis showed that the combined expression of ADAR1 and AIMP2 accounted for 45% of overall editing differences across tissues, whereas ADAR1 alone accounted for only 20%, highlighting the significant regulatory role of AIMP2 [tan-2017-RNA-editing-ADAR-abstract].

The Oncogenic Splice Variant AIMP2-DX2

Alternative splicing of AIMP2 pre-mRNA produces a variant lacking exon 2, designated AIMP2-DX2. This truncated protein functions as an oncogenic factor by competitively antagonizing the tumor suppressor activities of full-length AIMP2 [choi-2011-AIMP2-DX2-cancer-abstract]. AIMP2-DX2 retains the ability to bind target proteins including p53, TRAF2, and FBP, but lacks the functional domains required to mediate tumor suppression. As a result, AIMP2-DX2 competes with normal AIMP2 for target binding, effectively impairing its protective functions [choi-2011-AIMP2-DX2-cancer-abstract].

AIMP2-DX2 is specifically expressed in diverse cancer types including lung, breast, liver, bone, and stomach cancer, with expression levels increasing during cancer progression [choi-2011-AIMP2-DX2-cancer-abstract]. Higher ratios of AIMP2-DX2 to full-length AIMP2 correlate with poorer patient survival in lung cancer and chemoresistance in ovarian cancer [zhou-2020-AIMPs-cancer-review]. Transgenic mice expressing AIMP2-DX2 showed increased susceptibility to carcinogen-induced tumorigenesis, while suppression of AIMP2-DX2 reduced tumor growth in xenograft models [choi-2011-AIMP2-DX2-cancer-abstract].

Heat shock protein 70 (Hsp70) stabilizes AIMP2-DX2 through specific recognition of the variant, contributing to its accumulation in cancer cells [zhou-2020-AIMPs-cancer-review]. Therapeutic strategies targeting AIMP2-DX2 include trans-splicing ribozymes that selectively replace AIMP2-DX2 RNA with normal transcripts, small molecule inhibitors of protein-protein interactions, and shRNA-mediated suppression affecting EGFR/MAPK signaling [zhou-2020-AIMPs-cancer-review].

Role in Parkinson's Disease and Neurodegeneration

AIMP2 has emerged as a critical mediator of dopaminergic neurodegeneration in Parkinson's disease (PD). The protein was originally identified as a substrate of Parkin, an E3 ubiquitin ligase whose loss-of-function mutations cause autosomal recessive juvenile parkinsonism [corti-2003-parkin-substrate-abstract]. Wild-type Parkin promotes AIMP2 degradation through polyubiquitination and proteasomal degradation, while mutant Parkin fails to bind and degrade AIMP2, leading to its pathological accumulation [corti-2003-parkin-substrate-abstract].

AIMP2 accumulation has been documented in postmortem brain tissue from PD patients, with approximately two- to three-fold elevation in the substantia nigra [lee-2013-parthanatos-PD-abstract]. AIMP2 is present in Lewy bodies and coaggregates with alpha-synuclein, the hallmark pathological features of PD [lee-2013-parthanatos-PD-abstract]. Importantly, AIMP2 accumulation occurs not only in autosomal recessive juvenile PD with Parkin loss, but also in sporadic PD where Parkin E3 ligase activity becomes inactivated [lee-2013-parthanatos-PD-abstract].

The mechanism by which AIMP2 accumulation causes neurodegeneration involves direct activation of poly(ADP-ribose) polymerase-1 (PARP1) [lee-2013-parthanatos-PD-abstract]. Unexpectedly, AIMP2 activates PARP1 through direct protein-protein interaction in the nucleus, independently of DNA damage—the canonical trigger for PARP1 activation. This aberrant PARP1 activation triggers parthanatos, a cell death pathway characterized by excessive poly(ADP-ribose) (PAR) polymer formation, translocation of PAR to mitochondria, release of apoptosis-inducing factor (AIF), and subsequent large-scale DNA fragmentation [lee-2013-parthanatos-PD-abstract].

Transgenic mice overexpressing AIMP2 in brain neurons developed selective, age-dependent, progressive loss of substantia nigra pars compacta dopamine neurons, with 53-60% neuronal loss by 20 months of age [lee-2013-parthanatos-PD-abstract]. This was accompanied by motor deficits and striatal dopamine depletion. Critically, PARP1 inhibition through genetic deletion or pharmacological treatment completely prevented dopaminergic neuron loss, suggesting that brain-permeable PARP inhibitors may offer therapeutic benefit in PD [lee-2013-parthanatos-PD-abstract]. PAR polymer levels were elevated approximately 10-fold in diseased substantia nigra tissue from PD patients, supporting the translational relevance of this pathway [lee-2013-parthanatos-PD-abstract].

Interestingly, the oncogenic splice variant AIMP2-DX2 may have therapeutic potential in PD. Because DX2 competes with full-length AIMP2 for PARP1 activation but lacks the ability to trigger parthanatos, it has been proposed as a potential therapeutic target [zhou-2020-AIMPs-cancer-review]. However, the non-enzymatic nature of AIMP2 and its predominant localization within the tRNA synthetase complex make direct targeting challenging.

Hypomyelinating Leukodystrophy and Neurodevelopmental Function

Biallelic loss-of-function mutations in AIMP2 cause hypomyelinating leukodystrophy-17 (HLD17; OMIM 618006), a severe autosomal recessive neurodevelopmental disorder [shukla-2018-HLD17-abstract]. HLD17 was first described in four patients from two consanguineous Indian families carrying a homozygous c.105C>A transversion resulting in a Y35X nonsense mutation [shukla-2018-HLD17-abstract].

Affected individuals exhibit profound developmental impairment from infancy, never learning to walk or speak. Clinical features include early-onset multifocal seizures, severe spasticity with spastic quadriparesis, poor overall growth, and progressive microcephaly (up to -10 standard deviations) [shukla-2018-HLD17-abstract]. Brain imaging reveals multiple abnormalities including cerebral and cerebellar atrophy, thin corpus callosum, abnormal signals in the basal ganglia, and features suggesting hypo- or demyelination. Some patients may die in childhood [shukla-2018-HLD17-abstract].

Mechanistic studies in oligodendroglial cell models have shown that the Y35X mutant protein localizes aberrantly as aggregates in Golgi bodies, where it activates Golgi stress-responsive caspase-2 (CASP2), inhibiting oligodendrocyte differentiation [shukla-2018-HLD17-abstract]. Knockdown of CASP2 reversed the differentiation defects in cells expressing mutant AIMP2, suggesting a potential therapeutic target [shukla-2018-HLD17-abstract]. These findings indicate that AIMP2 plays essential roles in myelination and nervous system development beyond its canonical function in translation.

Evolutionary Considerations

AIMP2 is an evolutionary innovation of higher eukaryotes, with no identifiable homolog in yeast, bacteria, or archaea [park-2010-AIMPs-review-abstract]. The multi-tRNA synthetase complex and its auxiliary factors appear to have evolved as the translational machinery expanded in complexity during eukaryotic evolution. The protein displays a putative leucine-zipper motif and shares sequence patterns with protein domains involved in protein-protein interactions, suggesting it evolved to mediate the assembly of multiple enzymes into a coordinated complex.

The absence of AIMP2 in lower organisms means that the non-translational functions of AIMP2—including tumor suppression via p53, TGF-beta, Wnt, and TNF-alpha pathways—represent innovations that emerged specifically in higher eukaryotes. This suggests that the MSC may have been co-opted during evolution as a regulatory hub that coordinates protein synthesis with cell fate decisions.

Experimental Evidence and Methodological Approaches

The functional characterization of AIMP2 has relied on diverse experimental approaches spanning genetics, structural biology, cell biology, and animal models. Gene disruption studies in mice demonstrated the essential nature of AIMP2 for MSC integrity and organismal survival [kim-2002-p38-scaffold-abstract]. Biochemical reconstitution and co-immunoprecipitation experiments defined the protein-protein interaction network within the MSC and identified AIMP2's binding partners in signaling pathways [han-2008-p53-genotoxic-abstract][kim-2003-lung-differentiation-abstract].

X-ray crystallography of MSC subcomplexes provided atomic-resolution insights into the structural basis of complex assembly and the mechanisms of stress-induced disassembly [hahn-2019-DRS-AIMP2-structure-abstract][fang-2013-LysRS-AIMP2-structure-abstract]. Mutational analysis of key residues, particularly Ser156, confirmed the functional importance of phosphorylation sites identified through mass spectrometry [hahn-2019-DRS-AIMP2-structure-abstract][kim-2016-smurf2-cancer-abstract].

The tumor suppressor and neuroprotective functions of AIMP2 have been validated through multiple mouse models, including knockout, heterozygous, and transgenic approaches [kim-2003-lung-differentiation-abstract][yum-2016-Wnt-intestine-abstract][lee-2013-parthanatos-PD-abstract]. Human relevance has been established through analysis of postmortem brain tissue from PD patients, cancer cell line studies, and identification of disease-associated mutations in patient populations [han-2008-p53-genotoxic-abstract][lee-2013-parthanatos-PD-abstract][shukla-2018-HLD17-abstract].

Open Questions

Despite substantial progress in understanding AIMP2 function, several important questions remain:

1. MSC dynamics in vivo: How is the balance between MSC-bound and free AIMP2 regulated under different physiological conditions? What is the kinetics of AIMP2 dissociation and re-association with the MSC?

2. Tissue-specific functions: Why do AIMP2 mutations or accumulation affect specific cell types preferentially (e.g., dopamine neurons, oligodendrocytes, lung epithelial cells)? What accounts for this selective vulnerability?

3. AIMP2-DX2 regulation: What factors control the alternative splicing that generates AIMP2-DX2? How does Hsp70 selectively stabilize the oncogenic variant?

4. Therapeutic targeting: Can AIMP2 be effectively targeted for cancer therapy or neuroprotection given its non-enzymatic nature and multiple functions? Would enhancing AIMP2-DX2 be beneficial in Parkinson's disease without promoting tumorigenesis?

5. Evolutionary origins: When and how did AIMP2's non-translational functions evolve? What was the selective advantage that drove the acquisition of tumor suppressor activities by a translation factor?

6. Integration of signaling pathways: How does AIMP2 coordinate its multiple tumor suppressor functions? Are there conditions under which different pathways (p53, TGF-beta, Wnt, TNF-alpha) are preferentially activated?

7. Role of other AIMPs: What is the functional relationship between AIMP2 and the other auxiliary factors AIMP1 and AIMP3? Do they have overlapping or distinct non-translational functions?

8. ADAR regulation mechanism: What is the molecular mechanism by which AIMP2 promotes ADAR protein degradation? Does this involve ubiquitination pathways similar to its effects on FBP and TRAF2?

9. Clinical biomarkers: Can circulating AIMP2 or AIMP2-DX2 levels serve as diagnostic or prognostic biomarkers for cancer or neurodegeneration?

References

• [nicolaides-1995-JTV1-discovery-abstract] Nicolaides NC, Kinzler KW, Vogelstein B. "Analysis of the 5-prime region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene." Genomics. 1995;29:329-334. DOI: 10.1006/geno.1995.9997. PMID: 8666380.

• [kim-2002-p38-scaffold-abstract] Kim JY, Kang YS, Lee JW, Kim HJ, Ahn YH, Park H, Ko YG, Kim S. "p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance." Proc Natl Acad Sci USA. 2002;99(12):7912-7916. DOI: 10.1073/pnas.122110199. PMID: 12060739.

• [kim-2003-lung-differentiation-abstract] Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH, Kang JW, Lee SW, Han JM, Lee HW, Kim S. "Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation." Nat Genet. 2003;34(3):330-336. DOI: 10.1038/ng1182. PMID: 12819782.

• [corti-2003-parkin-substrate-abstract] Corti O, Hampe C, Koutnikova H, et al. "The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration." Hum Mol Genet. 2003;12(12):1427-1437. DOI: 10.1093/hmg/ddg159. PMID: 12783850.

• [han-2008-p53-genotoxic-abstract] Han JM, Park BJ, Park SG, Oh YS, Choi SJ, Lee SW, Hwang SK, Chang SH, Cho MH, Kim S. "AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53." Proc Natl Acad Sci USA. 2008;105(32):11206-11211. DOI: 10.1073/pnas.0800297105. PMID: 18695251. PMCID: PMC2516205.

• [choi-2009-TNF-TRAF2-abstract] Choi JW, Kim DG, Park MC, Um JY, Han JM, Park SG, Choi EC, Kim S. "AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2." J Cell Sci. 2009;122(15):2710-2715. DOI: 10.1242/jcs.049767. PMID: 19584093.

• [park-2010-AIMPs-review-abstract] Park SG, Choi EC, Kim S. "Aminoacyl-tRNA synthetase-interacting multifunctional proteins (AIMPs): A triad for cellular homeostasis." IUBMB Life. 2010;62(4):296-302. DOI: 10.1002/iub.324. PMID: 20306515.

• [choi-2011-AIMP2-DX2-cancer-abstract] Choi JW, Kim DG, Lee AE, Kim HR, Lee JY, Kwon NH, Kim S. "Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis." PLoS Genet. 2011;7(3):e1001351. DOI: 10.1371/journal.pgen.1001351. PMID: 21408208. PMCID: PMC3048369.

• [fang-2013-LysRS-AIMP2-structure-abstract] Fang P, Wang J, Bennett SP, Guo M. "Structural Switch of Lysyl-tRNA Synthetase between Translation and Transcription." Mol Cell. 2013;49:30-42. DOI: 10.1016/j.molcel.2012.10.010. PMID: 23159739. PDB: 4DPG.

• [lee-2013-parthanatos-PD-abstract] Lee Y, Karuppagounder SS, Shin JH, et al. "Parthanatos Mediates AIMP2-Activated Age-Dependent Dopaminergic Neuronal Loss." Nat Neurosci. 2013;16(10):1392-1400. DOI: 10.1038/nn.3500. PMID: 23974709. PMCID: PMC3785563.

• [kim-2016-smurf2-cancer-abstract] Kim DG, Lee JY, Kwon N, et al. "Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2." Cancer Res. 2016;76(11):3422-3436. DOI: 10.1158/0008-5472.CAN-15-3255. PMID: 27197198.

• [yum-2016-Wnt-intestine-abstract] Yum MK, Kang JS, Lee AE, Jo YW, Seo JY, Kim HA, Kim YY, Seong J, Lee EB, Kim JH, Han JM, Kim S, Kong YY. "AIMP2 Controls Intestinal Stem Cell Compartments and Tumorigenesis by Modulating Wnt/beta-Catenin Signaling." Cancer Res. 2016;76(15):4559-4568. DOI: 10.1158/0008-5472.CAN-15-3357. PMID: 27262173.

• [tan-2017-RNA-editing-ADAR-abstract] Tan MH, Li Q, Shanmugam R, et al. "Dynamic landscape and regulation of RNA editing in mammals." Nature. 2017;550:249-254. DOI: 10.1038/nature24041. PMID: 29022589.

• [shukla-2018-HLD17-abstract] Shukla A, et al. "Homozygosity for a nonsense variant in AIMP2 is associated with a progressive neurodevelopmental disorder with microcephaly, seizures and spastic quadriparesis." OMIM: 618006 (HLD17).

• [hahn-2019-DRS-AIMP2-structure-abstract] Hahn H, Park SH, Kim HJ, Kim S, Han BW. "The DRS-AIMP2-EPRS subcomplex acts as a pivot in the multi-tRNA synthetase complex." IUCrJ. 2019;6(Pt 5):958-967. DOI: 10.1107/S2052252519010790. PMID: 31576228. PMCID: PMC6760448. PDB: 6IY6.

• [zhou-2020-AIMPs-cancer-review] Zhou Z, Sun B, Huang S, Yu D, Zhang X. "Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer." Cell Death Dis. 2020;11(7):579. DOI: 10.1038/s41419-020-02794-2. PMID: 32709848. PMCID: PMC7382500.

Citations

1. choi-2009-TNF-TRAF2-abstract.md
2. choi-2011-AIMP2-DX2-cancer-abstract.md
3. corti-2003-parkin-substrate-abstract.md
4. fang-2013-LysRS-AIMP2-structure-abstract.md
5. hahn-2019-DRS-AIMP2-structure-abstract.md
6. han-2008-p53-genotoxic-abstract.md
7. kim-2002-p38-scaffold-abstract.md
8. kim-2003-lung-differentiation-abstract.md
9. kim-2016-smurf2-cancer-abstract.md
10. lee-2013-parthanatos-PD-abstract.md
11. nicolaides-1995-JTV1-discovery-abstract.md
12. park-2010-AIMPs-review-abstract.md
13. shukla-2018-HLD17-abstract.md
14. tan-2017-RNA-editing-ADAR-abstract.md
15. yum-2016-Wnt-intestine-abstract.md
16. zhou-2020-AIMPs-cancer-review.md

provider: falcon
model: Edison Scientific Literature
cached: true
start_time: '2026-01-18T19:07:00.575959'
end_time: '2026-01-18T19:07:00.578635'
duration_seconds: 0.0
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: AIMP2
gene_symbol: AIMP2
uniprot_accession: Q13155
protein_description: 'RecName: Full=Aminoacyl tRNA synthase complex-interacting
multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component
p38; AltName: Full=Protein JTV-1;'
gene_info: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin.
(IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 19

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q13155
• Protein Description: RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1;
• Gene Information: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin. (IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "AIMP2" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'AIMP2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene AIMP2 (gene ID: AIMP2, UniProt: Q13155) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q13155
• Protein Description: RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1;
• Gene Information: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin. (IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "AIMP2" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'AIMP2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene AIMP2 (gene ID: AIMP2, UniProt: Q13155) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human AIMP2 (Q13155) – Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 (p38/JTV-1)

Verification of target identity and domains
- Identity/organism: AIMP2 (aliases p38, JTV-1) is a nonenzymatic, human scaffold subunit of the cytosolic multi-aminoacyl-tRNA synthetase complex (MSC). Reviews and primary studies consistently describe AIMP2 as an essential architectural component of the MSC in Homo sapiens, matching UniProt Q13155 (human). AIMP2 belongs to the AIMP family (AIMP1/p43, AIMP2/p38, AIMP3/p18) (Zhou 2020; Liang 2015) (zhou2020rolesofaminoacyltrna pages 1-2, liang2015steppingoutof pages 4-6).
- Domains/architecture: AIMP2 harbors a C-terminal GST-like domain mediating interactions with aminoacyl‑tRNA synthetases (e.g., EPRS, DRS/KARS module), consistent with GST_C-like annotations. It interacts with EPRS largely via GST domain heterodimerization and with DRS via specific loop contacts; these domain-level features align with the thioredoxin-like/GST superfamily annotations in the database summary (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 1-2).

Key concepts and definitions
- Core role: AIMP2 is a central scaffold of the mammalian MSC (with several cytosolic ARSs). Beyond scaffolding, AIMP2 is stress-responsive and can be released from the MSC to execute signaling functions linked to apoptosis, tumor suppression, and innate immunity (Zhou 2020; Liang 2015) (zhou2020rolesofaminoacyltrna pages 1-2, liang2015steppingoutof pages 4-6).
- MSC integrity and essentiality: Genetic and biochemical data indicate AIMP2 is required for complex stability and organismal viability; loss perturbs aminoacylation activities of complex-bound synthetases and AIMP2 deficiency in mice is lethal or increases tumor susceptibility (Liang 2015) (liang2015steppingoutof pages 4-6).

Molecular interactions and pathways (current understanding)
- MSC binding partners: AIMP2 directly scaffolds multiple ARSs. Domain-resolved evidence shows EPRS binds the AIMP2 GST domain; DRS (aspartyl‑RS) binds via defined loop interactions. AIMP2 also connects MSC submodules containing RRS, KRS, and QRS (Zhou 2020; Liang 2015) (zhou2020rolesofaminoacyltrna pages 1-2, liang2015steppingoutof pages 4-6).
- Phosphorylation-dependent release and nuclear translocation: DNA damage triggers JNK-dependent phosphorylation and dissociation of AIMP2 from the MSC, nuclear translocation, and binding to p53 to protect it from degradation. TGF‑β signaling induces AIMP2 expression and nuclear translocation; p38 MAPK phosphorylates AIMP2 at S156, promoting release from the MSC and binding to Smurf2, which leads to FBP downregulation and c‑Myc suppression. An S156A mutant impairs these tumor‑suppressor functions (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).
- TNF/NF‑κB axis: AIMP2 enhances TNF‑α–dependent pro‑apoptotic signaling by promoting ubiquitin‑dependent degradation of TRAF2 via c‑IAP1 recruitment (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).
- Wnt pathway: AIMP2 binds DVL1, disrupting AXIN–DVL1 assembly, thereby inhibiting Wnt/β‑catenin signaling and modulating intestinal stem-cell compartments (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).

Cellular localization
- Basal: Predominantly cytosolic as a core MSC scaffold (Liang 2015; Zhou 2020) (liang2015steppingoutof pages 4-6, zhou2020rolesofaminoacyltrna pages 1-2).
- Stress-induced: Upon specific stress/signaling cues (DNA damage, TGF‑β, p38 MAPK activation), AIMP2 is released from the MSC and translocates to the nucleus to execute transcriptional/tumor‑suppressive functions (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).

Disease mechanisms and recent developments (prioritized 2023–2024)
Neurodegeneration/Parkinson’s disease
- AIMP2 as Parkin substrate and parthanatos mediator: Foundational work identifies AIMP2 as a parkin substrate; AIMP2 accumulation drives PARP‑1 overactivation and dopaminergic neuron loss via parthanatos. Parkin overexpression protects cells from AIMP2 toxicity, and interventions that reduce AIMP2 (e.g., VPS35-mediated lysosomal clearance) mitigate toxicity (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 2-4, zhou2020rolesofaminoacyltrna pages 12-12).
- 2024 update—bidirectional regulation by DX2: AIMP2’s exon‑2–deleted splice variant, DX2, antagonizes AIMP2. In neuronal models, DX2 translocates to the nucleus more rapidly under oxidative stress, binds PARP‑1 with apparently higher affinity than AIMP2, and inhibits PARP‑1–dependent neuronal death. In vivo, DX2 transgenics show neuroprotection in rotenone models; single intracranial AAV‑DX2 improved behavior/mobility in 6‑OHDA PD models. This positions DX2 as a candidate therapeutic that counters AIMP2‑PARP‑1–driven parthanatos (Lee 2024, Acta Neuropathol Commun., Jan 2024; https://doi.org/10.1186/s40478-023-01697-5) (lee2024bidirectionalregulationof pages 1-2).

Cancer
- Tumor suppressor functions of AIMP2: AIMP2 promotes apoptosis upon genotoxic stress (via p53 stabilization) and suppresses oncogenic signaling (e.g., c‑Myc via FBP degradation) after S156 phosphorylation and Smurf2 engagement (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).
- AIMP2‑DX2 splice variant (oncogenic): DX2 is upregulated in several cancers (lung, chemoresistant ovarian), competes with AIMP2 for p53 and TRAF2 binding, and promotes tumorigenesis/chemoresistance (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).
- 2022–present translational advance—KRAS stabilization by DX2 and small-molecule inhibitor: DX2 specifically binds the KRAS hypervariable region and G‑domain in the cytosol prior to farnesylation, blocking Smurf2‑mediated KRAS ubiquitination and increasing KRAS stability; DX2 levels correlate with KRAS in colon/lung cancers. A small molecule targeting the DX2–KRAS interface reduces KRAS levels and suppresses KRAS‑dependent tumor growth in vitro and in vivo (Nature Communications, May 2022; https://doi.org/10.1038/s41467-022-30149-2) (kim2022aimp2dx2providestherapeutic pages 1-2).

Antiviral/viral interactions
- 2023 host-targeting anti-HIV concept via AIMP2–LysRS interface: During HIV‑1 infection, S207‑phosphorylated LysRS is released from the MSC and supports HIV replication by producing Ap4A in the nucleus to activate USF2 and promote proviral transcription. An MSC‑derived AIMP2 peptide (AIMP2‑N36) that binds LysRS and stabilizes its MSC‑bound conformation suppresses HIV‑1 DNA transcription in cells without impairing LysRS canonical aminoacylation—demonstrating a translational strategy to restrain LysRS noncanonical pro‑HIV activity by leveraging AIMP2–LysRS binding (Nucleic Acids Research, Nov 2023; https://doi.org/10.1093/nar/gkad941) (tang2023humanlysyltrnasynthetase pages 9-11).
- 2024 EV71 antiviral mechanism: AIMP2 restricts Enterovirus 71 by recruiting the E3 ligase SMURF2 to promote proteasomal degradation of the viral 3D polymerase (Virologica Sinica, Aug 2024; https://doi.org/10.1016/j.virs.2024.06.009) (ren2024aimp2restrictsev71 pages 12-13).
- Additional viral context: Earlier summaries link AIMP2–viral interactions (e.g., influenza A NS2 stabilizing AIMP2 to promote M1 SUMOylation and viral replication), highlighting that viruses can modulate AIMP2 to reprogram host ubiquitin/SUMO pathways (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 12-12).

Current applications and implementations
- Gene therapy concept (PD): AAV‑mediated DX2 delivery mitigated behavioral deficits and neuronal death in toxin-based PD models in vivo, suggesting a potential disease-modifying approach targeting the AIMP2–PARP‑1 axis (Lee 2024; https://doi.org/10.1186/s40478-023-01697-5) (lee2024bidirectionalregulationof pages 1-2).
- Small molecules in oncology: A DX2–KRAS interface inhibitor reduced KRAS abundance and KRAS‑dependent tumor growth in preclinical models (Nature Communications, 2022; https://doi.org/10.1038/s41467-022-30149-2) (kim2022aimp2dx2providestherapeutic pages 1-2).
- Host-directed antivirals: The AIMP2‑N36 peptide strategy indicates that stabilizing MSC components to prevent noncanonical, virus-supportive functions of ARSs (e.g., LysRS) can attenuate HIV replication without suppressing translation (Nucleic Acids Research, 2023; https://doi.org/10.1093/nar/gkad941) (tang2023humanlysyltrnasynthetase pages 9-11).

Expert synthesis and analysis
- AIMP2 functions as a molecular switch: Under homeostasis, it scaffolds the MSC to support translation. Under stress or specific signaling (JNK, p38 MAPK; TGF‑β), phosphorylation‑dependent release allows nuclear relocalization where AIMP2 coordinates tumor suppressor pathways (p53 stabilization, c‑Myc suppression) and apoptotic signaling (TNF‑TRAF2 axis). The same release principle enables pathogenic roles in PD when AIMP2 accumulates and hyperactivates PARP‑1 parthanatos; conversely, the DX2 splice variant buffers AIMP2’s lethal interactions in neurons but can be oncogenic in proliferative tissues by neutralizing AIMP2 tumor-suppressor functions (Zhou 2020; Lee 2024) (zhou2020rolesofaminoacyltrna pages 6-8, lee2024bidirectionalregulationof pages 1-2).
- Therapeutic window considerations: Tissue context likely dictates whether enhancing AIMP2 (cancer) or antagonizing its interactions (neurodegeneration) is beneficial. The divergent effects of DX2 underscore this: neuroprotective in PD models by competing with AIMP2–PARP‑1, but tumor‑promoting via competition with AIMP2 at p53/TRAF2 and via KRAS stabilization (Lee 2024; Zhou 2020; Kim 2022) (lee2024bidirectionalregulationof pages 1-2, zhou2020rolesofaminoacyltrna pages 6-8, kim2022aimp2dx2providestherapeutic pages 1-2).
- Virology perspective: AIMP2 sits at an intersection of host translation machinery and ubiquitin signaling. EV71 studies reveal an intrinsic antiviral role (AIMP2→SMURF2→viral polymerase degradation), while HIV exploits release of LysRS from the AIMP2‑scaffolded MSC; constraining ARS release with an AIMP2‑derived peptide curtails HIV transcriptional activation, illustrating host-pathway leverage points (Tang 2023; Ren 2024) (tang2023humanlysyltrnasynthetase pages 9-11, ren2024aimp2restrictsev71 pages 12-13).

Relevant statistics and data
- PD models: DX2 transgenic mice exhibited neuroprotection in rotenone-induced damage; AAV‑DX2 improved motor behavior in 6‑OHDA models (qualitative summary from Lee 2024). These data provide preclinical proof-of-concept for targeting the AIMP2–PARP‑1 axis (Lee 2024; https://doi.org/10.1186/s40478-023-01697-5) (lee2024bidirectionalregulationof pages 1-2).
- Oncology models: Disrupting DX2–KRAS interaction lowered KRAS levels and suppressed KRAS‑dependent tumor growth in vitro and in vivo (Nature Communications 2022; https://doi.org/10.1038/s41467-022-30149-2) (kim2022aimp2dx2providestherapeutic pages 1-2).
- HIV replication assays: AIMP2‑N36 expression suppressed HIV-1 DNA transcription in single-cycle and multi-round infection without impairing LysRS aminoacylation, indicating a selective host-directed antiviral effect (Nucleic Acids Research 2023; https://doi.org/10.1093/nar/gkad941) (tang2023humanlysyltrnasynthetase pages 9-11).

Concise functional summary
- Primary role: Nonenzymatic scaffold subunit of the MSC, organizing multiple ARSs through GST‑like domain interfaces, essential for complex stability and organismal viability (Liang 2015; Zhou 2020) (liang2015steppingoutof pages 4-6, zhou2020rolesofaminoacyltrna pages 1-2).
- Stress signaling: Upon phosphorylation (JNK; p38 S156), AIMP2 dissociates from the MSC, translocates to the nucleus, binds p53 (stabilization), recruits Smurf2 to suppress c‑Myc (via FBP ubiquitination), facilitates TNF‑α–induced apoptosis (TRAF2–c‑IAP1), and modulates Wnt/DVL1 (Zhou 2020) (zhou2020rolesofaminoacyltrna pages 6-8).
- Disease links: AIMP2 accumulation drives PD‑relevant parthanatos via PARP‑1; DX2 antagonizes AIMP2 in neurons but is oncogenic in cancers and stabilizes KRAS. AIMP2 can also act as an antiviral restriction factor (EV71), and AIMP2–LysRS interactions can be exploited to suppress HIV transcription (Lee 2024; Kim 2022; Tang 2023; Ren 2024) (lee2024bidirectionalregulationof pages 1-2, kim2022aimp2dx2providestherapeutic pages 1-2, tang2023humanlysyltrnasynthetase pages 9-11, ren2024aimp2restrictsev71 pages 12-13).

Key sources with URLs and dates
- Lee MH et al. Bi-directional regulation of AIMP2 and its splice variant on PARP‑1-dependent neuronal cell death; therapeutic implication for Parkinson’s disease. Acta Neuropathol Commun. Jan 2024. https://doi.org/10.1186/s40478-023-01697-5 (lee2024bidirectionalregulationof pages 1-2).
- Zhou Z et al. Roles of aminoacyl‑tRNA synthetase‑interacting multi‑functional proteins in physiology and cancer. Cell Death Dis. Jul 2020. https://doi.org/10.1038/s41419-020-02794-2 (zhou2020rolesofaminoacyltrna pages 1-2, zhou2020rolesofaminoacyltrna pages 2-4, zhou2020rolesofaminoacyltrna pages 6-8, zhou2020rolesofaminoacyltrna pages 12-12).
- Liang D et al. AIMp1/p43 potentiates the link between innate and adaptive immunity. Int Rev Immunol. Sep 2015. https://doi.org/10.3109/08830185.2015.1077829 (liang2015steppingoutof pages 4-6).
- Kim DG et al. AIMP2‑DX2 provides therapeutic interface to control KRAS‑driven tumorigenesis. Nat Commun. May 2022. https://doi.org/10.1038/s41467-022-30149-2 (kim2022aimp2dx2providestherapeutic pages 1-2).
- Tang Y et al. Human lysyl‑tRNA synthetase phosphorylation promotes HIV‑1 proviral DNA transcription. Nucleic Acids Res. Nov 2023. https://doi.org/10.1093/nar/gkad941 (tang2023humanlysyltrnasynthetase pages 9-11).
- Ren J et al. AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase. Virologica Sinica. Aug 2024. https://doi.org/10.1016/j.virs.2024.06.009 (ren2024aimp2restrictsev71 pages 12-13).

Limitations and open questions
- High-resolution structural data for full-length human AIMP2 in complex with all cognate ARSs remains incomplete; most domain-level interactions are inferred from subcomplexes and reviews (Zhou 2020; Liang 2015) (zhou2020rolesofaminoacyltrna pages 1-2, liang2015steppingoutof pages 4-6).
- Translational balance: DX2 shows tissue‑specific duality (neuroprotective vs oncogenic). Defining safe delivery/induction paradigms will be crucial for clinical translation (Lee 2024; Kim 2022) (lee2024bidirectionalregulationof pages 1-2, kim2022aimp2dx2providestherapeutic pages 1-2).

References

1. (zhou2020rolesofaminoacyltrna pages 1-2): Zheng Zhou, Bao Sun, Shiqiong Huang, Dongsheng Yu, and Xiaochuan Zhang. Roles of aminoacyl-trna synthetase-interacting multi-functional proteins in physiology and cancer. Cell Death & Disease, Jul 2020. URL: https://doi.org/10.1038/s41419-020-02794-2, doi:10.1038/s41419-020-02794-2. This article has 62 citations and is from a peer-reviewed journal.

2. (liang2015steppingoutof pages 4-6): D. Liang, M. M. Halpert, V. Konduri, and W. K. Decker. Stepping out of the cytosol: aimp1/p43 potentiates the link between innate and adaptive immunity. International Reviews of Immunology, 34:367-381, Sep 2015. URL: https://doi.org/10.3109/08830185.2015.1077829, doi:10.3109/08830185.2015.1077829. This article has 28 citations and is from a peer-reviewed journal.

3. (zhou2020rolesofaminoacyltrna pages 6-8): Zheng Zhou, Bao Sun, Shiqiong Huang, Dongsheng Yu, and Xiaochuan Zhang. Roles of aminoacyl-trna synthetase-interacting multi-functional proteins in physiology and cancer. Cell Death & Disease, Jul 2020. URL: https://doi.org/10.1038/s41419-020-02794-2, doi:10.1038/s41419-020-02794-2. This article has 62 citations and is from a peer-reviewed journal.

4. (zhou2020rolesofaminoacyltrna pages 2-4): Zheng Zhou, Bao Sun, Shiqiong Huang, Dongsheng Yu, and Xiaochuan Zhang. Roles of aminoacyl-trna synthetase-interacting multi-functional proteins in physiology and cancer. Cell Death & Disease, Jul 2020. URL: https://doi.org/10.1038/s41419-020-02794-2, doi:10.1038/s41419-020-02794-2. This article has 62 citations and is from a peer-reviewed journal.

5. (zhou2020rolesofaminoacyltrna pages 12-12): Zheng Zhou, Bao Sun, Shiqiong Huang, Dongsheng Yu, and Xiaochuan Zhang. Roles of aminoacyl-trna synthetase-interacting multi-functional proteins in physiology and cancer. Cell Death & Disease, Jul 2020. URL: https://doi.org/10.1038/s41419-020-02794-2, doi:10.1038/s41419-020-02794-2. This article has 62 citations and is from a peer-reviewed journal.

6. (lee2024bidirectionalregulationof pages 1-2): Min Hak Lee, Ki-Hwan Um, Seok Won Lee, Ye Ji Sun, Da-Hye Gu, Young Ok Jo, Sung Hyun Kim, Wongi Seol, Hyorin Hwang, Kyunghwa Baek, and Jin Woo Choi. Bi-directional regulation of aimp2 and its splice variant on parp-1-dependent neuronal cell death; therapeutic implication for parkinson's disease. Acta Neuropathologica Communications, Jan 2024. URL: https://doi.org/10.1186/s40478-023-01697-5, doi:10.1186/s40478-023-01697-5. This article has 9 citations and is from a peer-reviewed journal.

7. (kim2022aimp2dx2providestherapeutic pages 1-2): Dae Gyu Kim, Yongseok Choi, Yuno Lee, Semi Lim, Jiwon Kong, JaeHa Song, Younah Roh, Dipesh S. Harmalkar, Kwanshik Lee, Ja-il Goo, Hye Young Cho, Ameeq Ul Mushtaq, Jihye Lee, Song Hwa Park, Doyeun Kim, Byung Soh Min, Kang Young Lee, Young Ho Jeon, Sunkyung Lee, Kyeong Lee, and Sunghoon Kim. Aimp2-dx2 provides therapeutic interface to control kras-driven tumorigenesis. Nature Communications, May 2022. URL: https://doi.org/10.1038/s41467-022-30149-2, doi:10.1038/s41467-022-30149-2. This article has 11 citations and is from a highest quality peer-reviewed journal.

8. (tang2023humanlysyltrnasynthetase pages 9-11): Yingke Tang, Ryan T Behrens, Corine St Gelais, Siqi Wu, Saravanan Vivekanandan, Ehud Razin, Pengfei Fang, Li Wu, Nathan Sherer, and Karin Musier-Forsyth. Human lysyl-trna synthetase phosphorylation promotes hiv-1 proviral dna transcription. Nucleic Acids Research, 51:12111-12123, Nov 2023. URL: https://doi.org/10.1093/nar/gkad941, doi:10.1093/nar/gkad941. This article has 4 citations and is from a highest quality peer-reviewed journal.

9. (ren2024aimp2restrictsev71 pages 12-13): Junrui Ren, Lei Yu, Qiuhan Zhang, Pengyu Ren, Yumeng Cai, Xueyun Wang, Ke Lan, and Shuwen Wu. Aimp2 restricts ev71 replication by recruiting smurf2 to promote the degradation of 3d polymerase. Virologica Sinica, 39:632-644, Aug 2024. URL: https://doi.org/10.1016/j.virs.2024.06.009, doi:10.1016/j.virs.2024.06.009. This article has 1 citations and is from a peer-reviewed journal.

Citations

1. zhou2020rolesofaminoacyltrna pages 1-2
2. liang2015steppingoutof pages 4-6
3. zhou2020rolesofaminoacyltrna pages 6-8
4. lee2024bidirectionalregulationof pages 1-2
5. tang2023humanlysyltrnasynthetase pages 9-11
6. zhou2020rolesofaminoacyltrna pages 12-12
7. zhou2020rolesofaminoacyltrna pages 2-4
8. https://doi.org/10.1186/s40478-023-01697-5
9. https://doi.org/10.1038/s41467-022-30149-2
10. https://doi.org/10.1093/nar/gkad941
11. https://doi.org/10.1016/j.virs.2024.06.009
12. https://doi.org/10.1038/s41419-020-02794-2
13. https://doi.org/10.3109/08830185.2015.1077829
14. https://doi.org/10.1038/s41419-020-02794-2,
15. https://doi.org/10.3109/08830185.2015.1077829,
16. https://doi.org/10.1186/s40478-023-01697-5,
17. https://doi.org/10.1038/s41467-022-30149-2,
18. https://doi.org/10.1093/nar/gkad941,
19. https://doi.org/10.1016/j.virs.2024.06.009,

provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-12-27T17:24:53'
end_time: '2025-12-27T17:43:20.735497'
duration_seconds: 1107.74
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: AIMP2
gene_symbol: AIMP2
uniprot_accession: Q13155
protein_description: 'RecName: Full=Aminoacyl tRNA synthase complex-interacting
multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component
p38; AltName: Full=Protein JTV-1;'
gene_info: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin.
(IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
top_p: 1.0
citation_count: 122

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q13155
• Protein Description: RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1;
• Gene Information: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin. (IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "AIMP2" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'AIMP2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene AIMP2 (gene ID: AIMP2, UniProt: Q13155) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

AIMP2 (JTV-1/p38) – Function, Interactions, and Clinical Significance

Gene Identity and Role in Translation

AIMP2 (ARS-interacting multi-functional protein 2, also known as JTV-1 or p38) is a human protein of 320 amino acids that serves as a non-catalytic scaffolding component of the multi-aminoacyl-tRNA synthetase complex (MSC) (www.ncbi.nlm.nih.gov) (www.nome.bio). This large complex comprises multiple aminoacyl-tRNA synthetases (eight canonical enzymes in higher eukaryotes, including the bifunctional Glu-Pro tRNA synthetase) together with three auxiliary factors (AIMP1/p43, AIMP2/p38, and AIMP3/p18) (pmc.ncbi.nlm.nih.gov). AIMP2 is required for the assembly and stability of the MSC, essentially acting as a glue that organizes the enzymes responsible for charging tRNAs during protein synthesis (www.ncbi.nlm.nih.gov) (www.antibodypedia.com). Consistent with this vital role, animal studies show that AIMP2 is indispensable: mice lacking Aimp2 die shortly after birth with severely reduced tRNA synthetase activity (www.nome.bio), underscoring its importance in maintaining the translation machinery.

Structurally, AIMP2 contains distinct domains that mediate its interactions within the complex. It has an N-terminal region that binds lysyl-tRNA synthetase (LysRS), a central segment harboring a presumed leucine-zipper motif, and a C-terminal glutathione S-transferase (GST)-like domain (pmc.ncbi.nlm.nih.gov). These domains allow AIMP2 to tether specific synthetases: for example, AIMP2’s GST-homology domain forms a dimer with the GST domain of EPRS (Glu-Pro tRNA synthetase), and together with methionyl-tRNA synthetase (MRS) and AIMP3, they assemble into a heterotetrameric subcomplex that is part of the MSC’s core architecture (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). AIMP2 also interacts with aspartyl-tRNA synthetase (AspRS) via specific loop-loop contacts between the two proteins (pmc.ncbi.nlm.nih.gov), and its N-terminal LysRS-binding motif recruits lysyl-tRNA synthetase into the complex (pmc.ncbi.nlm.nih.gov). Through these multiple attachments, AIMP2 ensures that the cohort of nine enzyme activities and the other scaffolds are optimally arranged, facilitating efficient aminoacylation of tRNAs during protein translation (www.antibodypedia.com) (pmc.ncbi.nlm.nih.gov). In summary, under normal conditions AIMP2 resides in the cytosol as an integral part of the translation apparatus, stabilizing the multisynthetase ensemble required for protein synthesis.

Stress Response and Tumor Suppressor Functions

Beyond its housekeeping role in translation, AIMP2 has critical signaling functions, especially in responses to cellular stress and regulation of cell death. AIMP2 is widely recognized as a tumor suppressor protein, and a growing body of evidence indicates that it links certain stress signals to apoptotic pathways (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, AIMP2 typically exerts these effects when it dissociates from the MSC and translocates to the nucleus or other locations in response to stress stimuli (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This release from the cytosolic complex is often triggered by phosphorylation events. For example, under genotoxic stress (DNA damage), c-Jun N-terminal kinase (JNK) phosphorylates AIMP2, causing it to detach from the MSC and migrate into the nucleus (pmc.ncbi.nlm.nih.gov). Similarly, TGF-β signaling can induce AIMP2 expression and phosphorylation at Ser-156 by p38 MAPK, promoting AIMP2’s nuclear translocation in certain contexts (e.g. lung cell differentiation) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In the nucleus, AIMP2 engages in multiple protein–protein interactions that promote apoptosis and inhibit proliferation.

p53 Activation in DNA Damage: One well-characterized function of AIMP2 is to stabilize and activate the tumor suppressor p53 during DNA damage responses. Upon DNA damage, liberated AIMP2 directly binds to p53 and protects it from proteasomal destruction by blocking the MDM2 ubiquitin ligase (pmc.ncbi.nlm.nih.gov). Han et al. (2008) first showed that AIMP2 (p38) can form a complex with p53, preventing MDM2-mediated ubiquitination and thereby increasing p53 levels and activity (pmc.ncbi.nlm.nih.gov). This mechanism enhances p53-dependent transcription of pro-apoptotic genes, tipping the balance toward cell cycle arrest or apoptosis in damaged cells. Cellular experiments support this role: AIMP2-deficient cells are resistant to apoptosis induced by DNA-damaging agents, whereas overexpression of AIMP2 sensitizes cells to genotoxic death signals (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Thus, AIMP2 acts as a p53 co-factor under stress conditions, explaining why reduced AIMP2 can compromise p53 function. Indeed, a haploinsufficient effect is observed in vivo: mice with only one functional Aimp2 gene show increased susceptibility to spontaneous tumors, consistent with impaired p53-mediated tumor suppression (pmc.ncbi.nlm.nih.gov). In summary, AIMP2 serves as a nuclear relay for DNA-damage signals, ensuring p53 is stabilized to eliminate cells with genomic insults.

TNF-α Pathway and Apoptosis: AIMP2 also interfaces with the extrinsic apoptosis pathway initiated by tumor necrosis factor-alpha (TNF-α). Choi et al. (2009) reported that AIMP2 enhances cellular sensitivity to TNF-α–induced death by targeting a key survival factor in the TNF pathway (pmc.ncbi.nlm.nih.gov). Specifically, AIMP2 binds to the adaptor protein TRAF2 (TNF receptor–associated factor 2) and promotes its ubiquitination and degradation via recruitment of the E3 ubiquitin ligase c-IAP1 (pmc.ncbi.nlm.nih.gov). This action removes TRAF2, which normally helps activate NF-κB and other pro-survival signals downstream of TNF receptors. In cells lacking AIMP2, TNF-α exposure results in markedly less apoptosis, indicating that TRAF2 remains intact to transmit survival signals (pmc.ncbi.nlm.nih.gov). Conversely, introducing exogenous AIMP2 restores the pro-apoptotic response to TNF-α (pmc.ncbi.nlm.nih.gov). In essence, AIMP2 acts as an apoptosis facilitator in the TNF pathway – by driving the ubiquitin-dependent turnover of TRAF2, it tilts the balance toward caspase activation and cell death (pmc.ncbi.nlm.nih.gov). This mechanism is another facet of AIMP2’s tumor-suppressive activity, as it ensures effective elimination of potentially cancerous cells in the presence of inflammatory cytokines. Notably, AIMP2 was initially identified as “p38” in the MSC, but later studies like Choi et al. showed it moonlights in TNF signaling (pubmed.ncbi.nlm.nih.gov). These findings highlight AIMP2’s broader role as a linker between the translational apparatus and cell death pathways.

Wnt/β-Catenin Signaling Regulation: Emerging research indicates AIMP2 can antagonize pro-growth signaling pathways such as Wnt/β-catenin. AIMP2 was found to interact with Dishevelled 1 (DVL1), a pivotal cytoplasmic component of Wnt signal transduction (pmc.ncbi.nlm.nih.gov). By binding DVL1, AIMP2 disrupts the formation of the DVL1–Axin complex that is normally required to inhibit the β-catenin destruction complex (pmc.ncbi.nlm.nih.gov). In one study, loss of AIMP2 led to uninhibited Wnt signaling; specifically, AIMP2^+/− mice (which express less AIMP2) showed enlarged intestinal stem cell compartments and were predisposed to intestinal tumors due to elevated Wnt/β-catenin activity (pmc.ncbi.nlm.nih.gov). Conversely, AIMP2 binding to DVL1 helped suppress β-catenin signaling, thereby restricting excessive cell proliferation in intestinal epithelium (pmc.ncbi.nlm.nih.gov). This Wnt-inhibitory function further explains AIMP2’s haploinsuppressive tumor suppression: even partial loss of AIMP2 can unleash Wnt-driven tumorigenesis (e.g. accelerating polyp formation in APC^Min/+ colon cancer models) (pmc.ncbi.nlm.nih.gov). Thus, AIMP2 plays a modulatory role in developmental signaling pathways, keeping proto-oncogenic signals like Wnt in check under normal circumstances.

c-Myc and FBP Degradation: Another critical target of AIMP2’s extratranslational activity is the c-Myc oncogene pathway. AIMP2 helps restrain c-Myc by promoting the degradation of FUBP1 (far upstream element-binding protein 1, also called FBP), which is a transcriptional activator of the MYC gene. Under growth-inhibitory signals such as TGF-β, AIMP2 gets phosphorylated (at Ser-156) and relocates to the nucleus where it partners with the HECT-domain E3 ligase Smurf2 (yonsei.elsevierpure.com) (pmc.ncbi.nlm.nih.gov). AIMP2 serves as the adaptor that brings Smurf2 to FUBP1, leading to ubiquitin-mediated proteolysis of FUBP1 (yonsei.elsevierpure.com). By removing FUBP1, AIMP2 effectively reduces c-Myc transcription, since FUBP1 normally binds the MYC promoter to enhance its expression. This pathway was elucidated by Kim et al. (2016), who showed that preventing AIMP2’s interaction with Smurf2 (through an oncogenic mutation in AIMP2) abrogated FUBP1 ubiquitination and allowed c-Myc levels to remain elevated, resulting in increased cellular transformation and tumorigenesis (yonsei.elsevierpure.com). In line with this, TGF-β stimulation was found to increase AIMP2 expression and nuclear translocation in certain cells, where AIMP2 then contributed to c-Myc downregulation and differentiation via FUBP1 degradation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Collectively, these findings position AIMP2 as a multifaceted suppressor of oncogenic programs: it can engage ubiquitin ligases (like Smurf2 or c-IAP1) to eliminate pro-survival or pro-growth factors (such as FUBP1 and TRAF2), thereby enforcing cell cycle arrest or apoptosis. As a 2020 review succinctly noted, although AIMP2’s full spectrum of functions is still being uncovered, it “usually shows tumor-suppressive activities”, and reducing AIMP2 (for instance, in heterozygous knockout mice) leads to greater tumor susceptibility (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Other Biological Roles in Neurons and Immunity

While AIMP2’s best-studied non-catalytic roles relate to tumor suppression, the protein has also been implicated in certain neurodegenerative and antiviral processes, highlighting its broad importance in cell fate decisions. In the nervous system, AIMP2 has been linked to Parkinson’s disease (PD) pathogenesis. AIMP2 was identified as a substrate of the Parkin E3 ubiquitin ligase, which is encoded by the PARK2 gene that is mutated in some familial PD (pmc.ncbi.nlm.nih.gov). Under normal conditions, Parkin ubiquitylates AIMP2 in neurons, targeting it for degradation and preventing its accumulation (pmc.ncbi.nlm.nih.gov). If Parkin is lost (as in PARK2-mutant PD patients), AIMP2 levels rise in dopaminergic neurons, with deleterious consequences. Lee et al. showed that excess AIMP2 in neurons can trigger PARP1 overactivation – AIMP2 physically interacts with poly(ADP-ribose) polymerase-1 and overactivates it, leading to accumulation of poly(ADP-ribose) polymers and a form of programmed cell death known as parthanatos (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This mechanism contributes to progressive loss of dopamine-producing neurons in the brain. Consistently, overexpression of AIMP2 in dopaminergic cell lines causes cell death, whereas increasing Parkin or the endosomal protein VPS35 (which helps clear AIMP2 via lysosomes) can rescue cells by promoting AIMP2 degradation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These findings suggest that, although AIMP2’s pro-apoptotic activity may protect against cancer, it can be harmful to post-mitotic neurons if not kept in check. Interestingly, a natural splice variant of AIMP2 (termed AIMP2-DX2, discussed below) appears to counteract AIMP2-induced toxicity in neurons: this shorter variant can bind PARP1 without activating it, thereby competitively blocking the toxic AIMP2–PARP1 interaction (pmc.ncbi.nlm.nih.gov) (www.nome.bio). Experimental gene therapy in PD models has leveraged this fact – introducing AIMP2-DX2 via an adeno-associated virus vector into the brains of PD mice protected their neurons and improved motor function, essentially by using the AIMP2-DX2 protein as a “decoy” to prevent endogenous AIMP2 from overactivating PARP1 (www.nome.bio). Such findings underscore the delicate balance of AIMP2’s activity: it must be carefully regulated to allow normal cell survival, and its dysregulation is a factor in neurodegeneration.

In the immune realm, recent research (2023–2024) revealed a surprising antiviral role for AIMP2. Ren et al. (2024) discovered that AIMP2 can act as a host restriction factor against enteroviruses, including the pathogen EV71 (which causes hand, foot and mouth disease) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In infected cells, AIMP2 was found to bind to the viral 3D RNA polymerase and recruit the ubiquitin ligase Smurf2, paralleling its behavior in cellular signaling pathways (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This interaction leads to polyubiquitination and proteasomal degradation of the viral polymerase, thereby inhibiting viral genome replication (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Overexpressing AIMP2 in cell culture produced a dose-dependent suppression of EV71: viral protein levels and RNA titers dropped markedly as AIMP2 levels were increased (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Moreover, the study showed that the antiviral effect was not limited to EV71 – AIMP2 similarly impeded replication of related enteroviruses (such as Coxsackievirus A16 and B1) by the same mechanism (pmc.ncbi.nlm.nih.gov). Intriguingly, enterovirus infection appears to actively downregulate AIMP2 expression, presumably as a viral counter-defense: EV71-infected cells showed a significant decrease in AIMP2 mRNA and protein over time (pmc.ncbi.nlm.nih.gov). This suggests the virus benefits from eliminating AIMP2 to evade its antiviral ubiquitination trap. The identification of AIMP2 in antiviral immunity is a striking example of a new function for this “multifunctional protein,” expanding its significance beyond the realms of translation and tumor biology. It also provides a potential avenue for therapy – boosting AIMP2 or mimicking its action might help combat certain viral infections (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). More broadly, AIMP2’s activities in disparate contexts (cancer suppression, neuronal cell death, and antiviral defense) all involve selective protein interactions and ubiquitin-mediated regulation, reinforcing the concept that AIMP2 is a versatile mediator that connects cellular stress signals to appropriate effector outcomes. As one analysis noted, AIMP2 acts as a multifaceted regulator of cell fate by targeting proteins like p53, FBP, TRAF2, and even viral enzymes for stability control (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Clinical Significance and Therapeutic Developments

Genetic Disorders (HLD17): Given AIMP2’s crucial role in protein synthesis and cell viability, it is not surprising that loss-of-function mutations in this gene lead to severe human disease. Recently, biallelic mutations in AIMP2 have been linked to a rare inherited neurodevelopmental syndrome classified as hypomyelinating leukodystrophy 17 (HLD17) (www.ncbi.nlm.nih.gov). Shukla et al. (2018) first reported a nonsense mutation (c.105C>A, p.Tyr35Ter) in AIMP2 in two unrelated families; affected children exhibited profound developmental delays, microcephaly, early-onset seizures, spastic quadriplegia, and MRI evidence of leukodystrophy (defective myelination of white matter) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). More recently, an infant from an Iranian family was found to carry a different AIMP2 nonsense variant (c.463A>T, p.Lys155Ter) in homozygous form, resulting in a similar clinical picture of progressive neurological deterioration, white-matter atrophy, severe anemia, and skeletal abnormalities (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These cases establish that complete loss of AIMP2 function in humans is neurotoxic, likely because the multisynthetase complex cannot assemble properly in the absence of AIMP2, leading to disrupted protein synthesis particularly in the energy-demanding brain. Consistent with that, cells derived from these patients show markedly reduced aminoacyl-tRNA synthetase activities and likely heightened susceptibility to apoptosis, mirroring the phenotype of AIMP2-null mice (www.nome.bio). There is currently no cure for AIMP2-related leukodystrophy, but these findings highlight the need for early genetic diagnosis (e.g. by whole-exome sequencing) in infants with unexplained leukodystrophy (pmc.ncbi.nlm.nih.gov). Efforts are underway to explore antisense oligonucleotide (ASO) therapies that could introduce small amounts of functional AIMP2 or modulate its splicing, as a personalized strategy for families affected by this ultra-rare disorder (www.nome.bio) (www.nome.bio).

Cancer and AIMP2-DX2 Variant: In oncology, AIMP2 is attracting interest both as a biomarker and as a therapeutic target, especially because of an alternatively spliced isoform called AIMP2-DX2. AIMP2-DX2 is a splice variant missing exon 2 of the normal transcript, and it produces a truncated protein (lacking residues 36–103 of full-length AIMP2) that retains the GST-like domains but behaves in a dominant-negative manner (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Importantly, AIMP2-DX2 binds many of the same partners as full-length AIMP2 – including p53, TRAF2, and FUBP1 – but it cannot execute the tumor-suppressive functions of AIMP2 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Instead, AIMP2-DX2 competes with the wild-type protein for binding to these targets, thereby impairing the pro-apoptotic and checkpoint activities of AIMP2. Under normal conditions, AIMP2-DX2 is barely expressed (and is often undetectable in healthy tissues) (pmc.ncbi.nlm.nih.gov). In cancers, however, this splice variant is frequently upregulated and has been identified as an oncogenic factor. It was shown that AIMP2-DX2 is highly expressed in a variety of tumors, with particularly elevated levels reported in lung cancer, colorectal and stomach cancers, pancreatic cancer, ovarian cancer, and nasopharyngeal carcinoma (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Ectopic overexpression of AIMP2-DX2 in experimental models can drive the transformation of normal cells into malignant cells, underscoring its actively tumorigenic potential (pmc.ncbi.nlm.nih.gov). Clinically, the presence of AIMP2-DX2 often correlates with worse outcomes. For instance, a 2020 study of acute myeloid leukemia (AML) patients found that 43.1% of cases had positive AIMP2-DX2 expression at diagnosis, and this subset had significantly shorter overall survival compared to AIMP2-DX2–negative patients (www.nome.bio). Likewise, analyses in solid tumors have linked a high AIMP2-DX2 to AIMP2 ratio with aggressive disease: in nasopharyngeal carcinoma, a higher DX2/full-length ratio was associated with poorer prognosis, suggesting this metric could stratify patients by risk (pmc.ncbi.nlm.nih.gov). Given these observations, AIMP2-DX2 is being actively explored as a drug target. One approach is to restore normal splicing – researchers have proposed using splice-switching antisense oligonucleotides to promote inclusion of exon 2, thereby shifting the balance back to the tumor-suppressive full-length AIMP2 (www.nome.bio) (www.nome.bio). Another strategy is to selectively destroy or inhibit the DX2 protein. High-throughput screening has identified small molecules that target AIMP2-DX2: for example, pyrimethamine (an old antimalarial drug) was found to induce ubiquitination and degradation of AIMP2-DX2 (IC_50 ≈ 0.7 μM) (www.nome.bio). A more potent investigational compound, BC-DXI-32982, disrupts the interaction between AIMP2-DX2 and mutant KRAS proteins, and it showed dose-dependent tumor growth suppression in preclinical models (IC_50 ≈ 0.18 μM) (www.nome.bio) (www.nome.bio). These agents are in preclinical development and exemplify a novel avenue of targeted therapy: by neutralizing AIMP2-DX2, they aim to unleash the natural tumor suppressor functions of AIMP2 in cancers that overexpress the splicing variant.

Prognostic and Therapeutic Biomarker: The expression status of AIMP2 (and its splice form) is also being studied as a biomarker to guide cancer treatment. Notably, a 2023 study employing multi-omics analysis of gliomas found that AIMP2 is a predictive biomarker for anti-angiogenic therapy in aggressive brain tumors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In recurrent glioblastoma (GBM), patients with high AIMP2 mRNA expression derived significantly greater benefit from treatments like bevacizumab (an anti-VEGF antibody) or regorafenib (a VEGFR/c-Met inhibitor). In two clinical trial cohorts, the high-AIMP2 subgroup showed marked improvement in survival on anti-angiogenic therapy (e.g. in one trial, median survival was substantially longer, with a hazard ratio ~4.75 favoring high AIMP2 patients) (pmc.ncbi.nlm.nih.gov). By contrast, low-AIMP2 tumors did not respond as well to these therapies. The study further identified specific CpG methylation sites in the AIMP2 gene whose methylation status correlated with AIMP2 expression and treatment outcomes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For example, hypomethylation at a particular AIMP2 promoter CpG (cg04317940) was associated with elevated AIMP2 and better response to bevacizumab, suggesting an epigenetic marker for patient stratification (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Mechanistically, the link between AIMP2 and angiogenesis may stem from AIMP2’s ability to modulate factors like FUBP1 and TRAF2 that influence VEGF signaling pathways (pmc.ncbi.nlm.nih.gov). In any case, these findings provide “proof-of-concept” that AIMP2 levels can inform therapy decisions. It is an example of translating the functional knowledge of AIMP2 into a practical clinical test: measuring AIMP2 (and AIMP2-DX2) expression or methylation in tumors could help predict which patients will benefit from certain treatments (such as anti-vascular therapies in GBM) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This concept may extend to other cancers; as noted earlier, low AIMP2 or high DX2 often signifies a more malignant phenotype, so therapies that either compensate for lost AIMP2 (e.g. via TGF-β induction or pharmacologic stabilization of p53) or specifically target DX2-harboring cells are of high interest.

Expert Perspectives: AIMP2 exemplifies how a classical “housekeeping” protein has evolved additional “moonlighting” functions in higher eukaryotes (pmc.ncbi.nlm.nih.gov). Originally characterized as part of the translation machinery, it is now clear that AIMP2 doubles as a sensor and mediator in multiple signaling pathways that maintain cellular homeostasis. Its ability to shuttle from the cytosolic multisynthetase complex to other cellular compartments (nucleus, membrane complexes, etc.) in response to stress allows it to coordinate the cell’s decision to grow, differentiate, or undergo apoptosis. As a recent review summarized, the three MSC scaffolds (AIMP1, AIMP2, AIMP3) are not merely passive assembly factors – they are “generally considered as auxiliary proteins” that have acquired extra domains/motifs enabling new signaling functions, often acting as tumor suppressors (pmc.ncbi.nlm.nih.gov). In the case of AIMP2, those appended domains (like the GST module) and post-translational modifications (like stress-induced phosphorylation) provide a platform for interacting with various cellular proteins. AIMP2 commonly works by bridging molecules: it brings together a substrate (p53, TRAF2, FBP, or a viral polymerase) with a ubiquitin ligase (MDM2, c-IAP1, Smurf2) or blocks such an interaction, thereby governing the substrate’s stability. This mode of action – serving as an adaptor or competitor in ubiquitin pathways – underlies its suppressive effect on oncogenesis and its pro-apoptotic role in stressed cells (yonsei.elsevierpure.com) (pmc.ncbi.nlm.nih.gov). However, that same pro-apoptotic property necessitates tight regulation, as evidenced by the neurodegenerative impact when AIMP2 is unchecked in Parkinson’s disease models (pmc.ncbi.nlm.nih.gov). Therapeutically, restoring the balance of AIMP2 activity is a key theme: in cancer, augmenting AIMP2 or silencing its antagonist splice form (DX2) is a promising strategy, whereas in neuronal diseases, dampening AIMP2’s toxic interaction with PARP1 has been shown to be beneficial (www.nome.bio) (pmc.ncbi.nlm.nih.gov). Ongoing research in 2023–2024 continues to unveil new facets – from solving the three-dimensional structure of AIMP2-DX2 (to aid drug design) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), to exploratory trials of AIMP2-targeted therapies. In summary, AIMP2 is a multifaceted protein that operates at the nexus of protein synthesis and cell signaling. Its primary function is to maintain translational homeostasis in the cytosol, but under the right cues it switches into a regulatory role, safeguarding the organism by triggering apoptosis in damaged or dangerous cells and even defending against viral invasion. This duality makes AIMP2 an intriguing target for medical intervention, as manipulating its levels or interactions could combat diseases ranging from cancer to neurodegeneration. The latest studies and expert analyses highlight AIMP2 as a paradigm of how a core translational factor can be repurposed by the cell to serve as a “guardian” against a variety of threats (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). With its broad influence on critical pathways and a growing recognition in clinical research, AIMP2 is likely to remain an important focus in both fundamental biology and translational medicine in the years to come.

References: Publications and database entries are cited in-line above (with source URLs and identifiers). Key sources include: RefSeq/NCBI Gene summaries (2016), primary research articles by Choi et al. (2009) (pmc.ncbi.nlm.nih.gov), Han et al. (2008) (pmc.ncbi.nlm.nih.gov), Park et al. (2010), Kim et al. (2016) (yonsei.elsevierpure.com), and others, as well as recent reviews in Cell Death & Disease (Zhou et al., 2020) (pmc.ncbi.nlm.nih.gov) and BMB Reports (Kim et al., 2024) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These sources, along with the latest studies from 2023–2024 (e.g. Ren et al., 2024 on antiviral function (pmc.ncbi.nlm.nih.gov), and Noor et al., 2023 on glioblastoma biomarkers (pmc.ncbi.nlm.nih.gov)), provide the current understanding of AIMP2’s multifunctional roles and its relevance to human health and disease. The evidence outlined offers a comprehensive view of AIMP2 as both a critical translational scaffold and a versatile signaling hub, reflecting the protein’s evolutionary expansion from a “housekeeper” to a key regulator of cellular fate (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Citations

1. AnnotationURLCitation(end_index=510, start_index=339, title='AIMP2 aminoacyl tRNA synthetase complex interacting multifunctional protein 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Term=7965#:~:text=Also%20known%20as%20P38%3B%20JTV1%3B,provided%20by%20RefSeq%2C%20May%202016')
2. AnnotationURLCitation(end_index=643, start_index=511, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=AIMP2%20,essential%20for%20two%20cellular%20functions')
3. AnnotationURLCitation(end_index=1020, start_index=885, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Aminoacyl,suppressive%20activities.%20In%20addition')
4. AnnotationURLCitation(end_index=1369, start_index=1199, title='AIMP2 aminoacyl tRNA synthetase complex interacting multifunctional protein 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Term=7965#:~:text=The%20protein%20encoded%20by%20this,provided%20by%20RefSeq%2C%20May%202016')
5. AnnotationURLCitation(end_index=1553, start_index=1370, title='- AIMP2 antibodies | Antibodypedia', type='url_citation', url='https://www.antibodypedia.com/gene_details.php?ensembl_id=ENSG00000106305#:~:text=The%20protein%20encoded%20by%20this,provided%20by%20RefSeq%2C%20May%202016')
6. AnnotationURLCitation(end_index=1874, start_index=1727, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=activator%20of%20MYC%2C%20thereby%20controlling,cell%20proliferation')
7. AnnotationURLCitation(end_index=2366, start_index=2237, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=al,sequence%20patterns%2C%20which%20are%20the')
8. AnnotationURLCitation(end_index=2822, start_index=2690, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=aspartyl,AIMP2%20by%20hydrogen%20bonds%20between')
9. AnnotationURLCitation(end_index=2954, start_index=2823, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=the%20%CE%B17,bound%20to%20AIMP3%2C%20and%20the')
10. AnnotationURLCitation(end_index=3204, start_index=3072, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=aspartyl,AIMP2%20by%20hydrogen%20bonds%20between')
11. AnnotationURLCitation(end_index=3422, start_index=3293, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=al,sequence%20patterns%2C%20which%20are%20the')
12. AnnotationURLCitation(end_index=3821, start_index=3638, title='- AIMP2 antibodies | Antibodypedia', type='url_citation', url='https://www.antibodypedia.com/gene_details.php?ensembl_id=ENSG00000106305#:~:text=The%20protein%20encoded%20by%20this,provided%20by%20RefSeq%2C%20May%202016')
13. AnnotationURLCitation(end_index=3954, start_index=3822, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=aspartyl,AIMP2%20by%20hydrogen%20bonds%20between')
14. AnnotationURLCitation(end_index=4659, start_index=4522, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=form%20a%20multi,DX2%2C%20and%20AIMP3.%20Also%2C%20we')
15. AnnotationURLCitation(end_index=4764, start_index=4660, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=AIMP2%20and%20cancer')
16. AnnotationURLCitation(end_index=5069, start_index=4930, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=apoptosis,mediated%20ubiquitination%20and%20degradation')
17. AnnotationURLCitation(end_index=5222, start_index=5070, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=discovered%20that%20upon%20TGF,the%20ubiquitination%20of%20FBP%20and')
18. AnnotationURLCitation(end_index=5634, start_index=5475, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=match%20at%20L376%20apoptosis,mediated%20ubiquitination%20and%20degradation')
19. AnnotationURLCitation(end_index=5998, start_index=5832, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=tumorigenesis.%20Moreover%2C%20TGF,which%20stimulated%20the%20ubiquitination%20and')
20. AnnotationURLCitation(end_index=6151, start_index=5999, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=discovered%20that%20upon%20TGF,the%20ubiquitination%20of%20FBP%20and')
21. AnnotationURLCitation(end_index=6719, start_index=6580, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=apoptosis,mediated%20ubiquitination%20and%20degradation')
22. AnnotationURLCitation(end_index=7049, start_index=6891, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=have%20demonstrated%20that%20AIMP2%20acts,Additionally%2C%20it%20promotes')
23. AnnotationURLCitation(end_index=7566, start_index=7406, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=It%20is%20reported%20that%20AIMP2,supported%20that%20the%20decreased%20AIMP2')
24. AnnotationURLCitation(end_index=7734, start_index=7567, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=levels%20in%20heterozygous%20AIMP2%20mice,AIMP2%20enhanced%20the%20sensitivity%20to')
25. AnnotationURLCitation(end_index=8225, start_index=8065, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=It%20is%20reported%20that%20AIMP2,supported%20that%20the%20decreased%20AIMP2')
26. AnnotationURLCitation(end_index=8808, start_index=8659, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=of%20p53,Conversely%2C%20exogenous%20supplementation%20of%20AIMP2')
27. AnnotationURLCitation(end_index=9161, start_index=9002, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=match%20at%20L384%20enhanced%20the,This%20finding%20suggests%20that%20AIMP2')
28. AnnotationURLCitation(end_index=9576, start_index=9427, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=of%20p53,Conversely%2C%20exogenous%20supplementation%20of%20AIMP2')
29. AnnotationURLCitation(end_index=9812, start_index=9663, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=of%20p53,Conversely%2C%20exogenous%20supplementation%20of%20AIMP2')
30. AnnotationURLCitation(end_index=10163, start_index=10004, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=match%20at%20L384%20enhanced%20the,This%20finding%20suggests%20that%20AIMP2')
31. AnnotationURLCitation(end_index=10636, start_index=10486, title='AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2 - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19584093/#:~:text=degradation%20of%20TRAF2%20,in%20a%20macromolecular%20protein%20complex')
32. AnnotationURLCitation(end_index=11152, start_index=11018, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Hemizygous%20deletion%20of%20AIMP2%20increased,Min')
33. AnnotationURLCitation(end_index=11430, start_index=11296, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Hemizygous%20deletion%20of%20AIMP2%20increased,Min')
34. AnnotationURLCitation(end_index=11815, start_index=11681, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Hemizygous%20deletion%20of%20AIMP2%20increased,Min')
35. AnnotationURLCitation(end_index=12100, start_index=11966, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Hemizygous%20deletion%20of%20AIMP2%20increased,Min')
36. AnnotationURLCitation(end_index=12465, start_index=12331, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Hemizygous%20deletion%20of%20AIMP2%20increased,Min')
37. AnnotationURLCitation(end_index=13316, start_index=13104, title='Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2 - Yonsei University', type='url_citation', url='https://yonsei.elsevierpure.com/en/publications/oncogenic-mutation-of-aimp2p38-inhibits-its-tumor-suppressive-int#:~:text=responsible%20for%20AIMP2,Smurf2%20and%20suggest%20that%20the')
38. AnnotationURLCitation(end_index=13469, start_index=13317, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=discovered%20that%20upon%20TGF,the%20ubiquitination%20of%20FBP%20and')
39. AnnotationURLCitation(end_index=13776, start_index=13583, title='Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2 - Yonsei University', type='url_citation', url='https://yonsei.elsevierpure.com/en/publications/oncogenic-mutation-of-aimp2p38-inhibits-its-tumor-suppressive-int#:~:text=c,also%20inhibited%20nuclear%20export%20of')
40. AnnotationURLCitation(end_index=14401, start_index=14208, title='Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2 - Yonsei University', type='url_citation', url='https://yonsei.elsevierpure.com/en/publications/oncogenic-mutation-of-aimp2p38-inhibits-its-tumor-suppressive-int#:~:text=c,also%20inhibited%20nuclear%20export%20of')
41. AnnotationURLCitation(end_index=14788, start_index=14622, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=tumorigenesis.%20Moreover%2C%20TGF,which%20stimulated%20the%20ubiquitination%20and')
42. AnnotationURLCitation(end_index=14941, start_index=14789, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=discovered%20that%20upon%20TGF,the%20ubiquitination%20of%20FBP%20and')
43. AnnotationURLCitation(end_index=15641, start_index=15481, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=It%20is%20reported%20that%20AIMP2,supported%20that%20the%20decreased%20AIMP2')
44. AnnotationURLCitation(end_index=15809, start_index=15642, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=levels%20in%20heterozygous%20AIMP2%20mice,AIMP2%20enhanced%20the%20sensitivity%20to')
45. AnnotationURLCitation(end_index=16464, start_index=16323, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Interestingly%2C%20AIMP2%20was%20a%20Parkin,showed%20that')
46. AnnotationURLCitation(end_index=16732, start_index=16591, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Interestingly%2C%20AIMP2%20was%20a%20Parkin,showed%20that')
47. AnnotationURLCitation(end_index=17302, start_index=17142, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=match%20at%20L188%20AIMP2%20accumulation,to%20delay%20the%20progression%20of')
48. AnnotationURLCitation(end_index=17472, start_index=17303, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=AIMP2%20accumulation%20overactivated%20poly%28ADP,to%20delay%20the%20progression%20of')
49. AnnotationURLCitation(end_index=17935, start_index=17794, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Interestingly%2C%20AIMP2%20was%20a%20Parkin,showed%20that')
50. AnnotationURLCitation(end_index=18077, start_index=17936, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=associated%20protein%2035%20,USP29%29%2C%20resulting%20in')
51. AnnotationURLCitation(end_index=18625, start_index=18510, title="Bi-directional regulation of AIMP2 and its splice variant on PARP-1-dependent neuronal cell death; Therapeutic implication for Parkinson's disease - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10765824/#:~:text=disease%20,1%20more%20strongly')
52. AnnotationURLCitation(end_index=18808, start_index=18626, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=Gene%20therapy%3A%20AAV2%20vectors%20delivering,DX2%20overexpression%20showing%20therapeutic%20efficacy')
53. AnnotationURLCitation(end_index=19296, start_index=19124, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=match%20at%20L240%20Gene%20therapy%3A,DX2%20overexpression%20showing%20therapeutic%20efficacy')
54. AnnotationURLCitation(end_index=19921, start_index=19764, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=we%20identified%20a%20novel%20host,the%20antiviral%20effect%20of%20AIMP2')
55. AnnotationURLCitation(end_index=20072, start_index=19922, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=In%20this%20study%2C%20we%20found,Our%20findings%20suggest%20that')
56. AnnotationURLCitation(end_index=20406, start_index=20249, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=we%20identified%20a%20novel%20host,the%20antiviral%20effect%20of%20AIMP2')
57. AnnotationURLCitation(end_index=20569, start_index=20407, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=AIMP2%20recruits%20the%20E3%20ligase,and%20degradation%20of%203D%20polymerase')
58. AnnotationURLCitation(end_index=20870, start_index=20713, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=we%20identified%20a%20novel%20host,the%20antiviral%20effect%20of%20AIMP2')
59. AnnotationURLCitation(end_index=21033, start_index=20871, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=AIMP2%20recruits%20the%20E3%20ligase,and%20degradation%20of%203D%20polymerase')
60. AnnotationURLCitation(end_index=21342, start_index=21203, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=match%20at%20L322%20amounts%20of,qPCR%20analysis%20was')
61. AnnotationURLCitation(end_index=21493, start_index=21343, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=In%20this%20study%2C%20we%20found,Our%20findings%20suggest%20that')
62. AnnotationURLCitation(end_index=21843, start_index=21693, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=In%20this%20study%2C%20we%20found,Our%20findings%20suggest%20that')
63. AnnotationURLCitation(end_index=22195, start_index=22061, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=3,was%20downregulated%20during%20EV71%20infection')
64. AnnotationURLCitation(end_index=22824, start_index=22634, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=regulatory%20function%20of%20AIMP2%20during,development%20of%20antienteroviral%20therapeutic%20strategies')
65. AnnotationURLCitation(end_index=22975, start_index=22825, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=In%20this%20study%2C%20we%20found,Our%20findings%20suggest%20that')
66. AnnotationURLCitation(end_index=23616, start_index=23474, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=tumorigenesis%20%282,suppressive%20activity%20of%20native')
67. AnnotationURLCitation(end_index=23774, start_index=23617, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=we%20identified%20a%20novel%20host,the%20antiviral%20effect%20of%20AIMP2')
68. AnnotationURLCitation(end_index=24359, start_index=24195, title='AIMP2 aminoacyl tRNA synthetase complex interacting multifunctional protein 2 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Term=7965#:~:text=Also%20known%20as%20P38%3B%20JTV1%3B,provided%20by%20RefSeq%2C%20May')
69. AnnotationURLCitation(end_index=24831, start_index=24672, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=variant%20%28c.105C%20,Iranian%20infant%20with%20progressive%20neurological')
70. AnnotationURLCitation(end_index=24933, start_index=24832, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=in%20AIMP2%20,MRI')
71. AnnotationURLCitation(end_index=25391, start_index=25230, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=homozygous%20state%20in%20exon%203,was%20confirmed%20by%20target%20sequencing')
72. AnnotationURLCitation(end_index=25551, start_index=25392, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=variant%20%28c.105C%20,Iranian%20infant%20with%20progressive%20neurological')
73. AnnotationURLCitation(end_index=26173, start_index=26026, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=activator%20of%20MYC%2C%20thereby%20controlling,cell%20proliferation')
74. AnnotationURLCitation(end_index=26536, start_index=26378, title='Case Report: Mutation in AIMP2/P38, the Scaffold for the Multi-Trna Synthetase Complex, and Association With Progressive Neurodevelopmental Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8820504/#:~:text=match%20at%20L47%20AIMP2%20mutation,well%20as%20for%20disease%20management')
75. AnnotationURLCitation(end_index=26906, start_index=26774, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=match%20at%20L275%20ASOs%20targeting,length%20protein')
76. AnnotationURLCitation(end_index=27057, start_index=26907, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=match%20at%20L372%20%2A%20AIMP2,ASOs%20promoting%20exon%202%20inclusion')
77. AnnotationURLCitation(end_index=27647, start_index=27494, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=AIMP2%20is%20a%2035%20kDa,produce%20a%20splicing%20variant%20lacking')
78. AnnotationURLCitation(end_index=27778, start_index=27648, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=exon%202%2C%20known%20as%20AIMP2,Additionally')
79. AnnotationURLCitation(end_index=28101, start_index=27959, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=tumorigenesis%20%282,suppressive%20activity%20of%20native')
80. AnnotationURLCitation(end_index=28255, start_index=28102, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=AIMP2%20is%20a%2035%20kDa,produce%20a%20splicing%20variant%20lacking')
81. AnnotationURLCitation(end_index=28671, start_index=28520, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=competitive%20interactions%20with%20FBP%2C%20TRAF2%2C,2B%29%20%285')
82. AnnotationURLCitation(end_index=29183, start_index=29019, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=with%20the%20aggressiveness%20of%20certain,suppressive%20activity%20of%20native')
83. AnnotationURLCitation(end_index=29335, start_index=29184, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=competitive%20interactions%20with%20FBP%2C%20TRAF2%2C,2B%29%20%285')
84. AnnotationURLCitation(end_index=29666, start_index=29515, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=competitive%20interactions%20with%20FBP%2C%20TRAF2%2C,2B%29%20%285')
85. AnnotationURLCitation(end_index=30161, start_index=29989, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=competitively%20inhibiting%20AIMP2%20tumor,associated%20with%20decreased%20overall%20survival')
86. AnnotationURLCitation(end_index=30558, start_index=30420, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=AIMP2,therapeutic%20strategy%20for%20cancer%20control')
87. AnnotationURLCitation(end_index=31007, start_index=30875, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=match%20at%20L275%20ASOs%20targeting,length%20protein')
88. AnnotationURLCitation(end_index=31128, start_index=31008, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=ASOs%20targeting%20AIMP2,length%20protein')
89. AnnotationURLCitation(end_index=31566, start_index=31420, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=Multiple%20compounds%20targeting%20AIMP2,to%20preclinical%20testing')
90. AnnotationURLCitation(end_index=31926, start_index=31789, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=match%20at%20L254%20%2A%20BC,dependent%20tumor%20reduction')
91. AnnotationURLCitation(end_index=32044, start_index=31927, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=%2A%20BC,dependent%20tumor%20reduction')
92. AnnotationURLCitation(end_index=32791, start_index=32620, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=antiangiogenic%20drugs%2C%20we%20found%20that,cell%20analysis%20revealed%20homogeneous')
93. AnnotationURLCitation(end_index=32954, start_index=32792, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=match%20at%20L51%20This%20study,methylation%20status%20offer%20a%20clinically')
94. AnnotationURLCitation(end_index=33576, start_index=33405, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=antiangiogenic%20drugs%2C%20we%20found%20that,cell%20analysis%20revealed%20homogeneous')
95. AnnotationURLCitation(end_index=33984, start_index=33813, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=antiangiogenic%20drugs%2C%20we%20found%20that,cell%20analysis%20revealed%20homogeneous')
96. AnnotationURLCitation(end_index=34167, start_index=33985, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=%281.17%E2%80%934.49%29%2C%20P%20%3D%200.015%5D.%20AIMP2,cell%20analysis%20revealed%20homogeneous')
97. AnnotationURLCitation(end_index=34547, start_index=34376, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=antiangiogenic%20drugs%2C%20we%20found%20that,cell%20analysis%20revealed%20homogeneous')
98. AnnotationURLCitation(end_index=34730, start_index=34548, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=%281.17%E2%80%934.49%29%2C%20P%20%3D%200.015%5D.%20AIMP2,cell%20analysis%20revealed%20homogeneous')
99. AnnotationURLCitation(end_index=35035, start_index=34899, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=match%20at%20L99%20,33%2C%2034%29%20that%20modulate')
100. AnnotationURLCitation(end_index=35591, start_index=35422, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=This%20study%20identifies%20AIMP2%20as,methylation%20status%20offer%20a%20clinically')
101. AnnotationURLCitation(end_index=35783, start_index=35592, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=groups%20indicate%20that%20AIMPs%2C%20particularly,antiangiogenic%20monotherapy%20was%20more%20efficacious')
102. AnnotationURLCitation(end_index=36371, start_index=36250, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=Aminoacyl,as%20a%20cleavage%20product')
103. AnnotationURLCitation(end_index=37256, start_index=37093, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=systems%2C%20eight%20ARSs%20and%20three,this%20review%2C%20we%20summarize%20the')
104. AnnotationURLCitation(end_index=38078, start_index=37885, title='Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2 - Yonsei University', type='url_citation', url='https://yonsei.elsevierpure.com/en/publications/oncogenic-mutation-of-aimp2p38-inhibits-its-tumor-suppressive-int#:~:text=c,also%20inhibited%20nuclear%20export%20of')
105. AnnotationURLCitation(end_index=38238, start_index=38079, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=match%20at%20L384%20enhanced%20the,This%20finding%20suggests%20that%20AIMP2')
106. AnnotationURLCitation(end_index=38534, start_index=38412, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=degradation%20of%20AIMP2,showed%20that')
107. AnnotationURLCitation(end_index=39003, start_index=38821, title='AIMP2 Gene Disorders: Research Update and Personalized ASO Therapy Options — Nome — Nome', type='url_citation', url='https://www.nome.bio/blog/aimp2-research-aso-therapy#:~:text=Gene%20therapy%3A%20AAV2%20vectors%20delivering,DX2%20overexpression%20showing%20therapeutic%20efficacy')
108. AnnotationURLCitation(end_index=39119, start_index=39004, title="Bi-directional regulation of AIMP2 and its splice variant on PARP-1-dependent neuronal cell death; Therapeutic implication for Parkinson's disease - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10765824/#:~:text=disease%20,1%20more%20strongly')
109. AnnotationURLCitation(end_index=39416, start_index=39263, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=AIMP2%20is%20a%2035%20kDa,produce%20a%20splicing%20variant%20lacking')
110. AnnotationURLCitation(end_index=39547, start_index=39417, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=exon%202%2C%20known%20as%20AIMP2,Additionally')
111. AnnotationURLCitation(end_index=40482, start_index=40345, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=form%20a%20multi,DX2%2C%20and%20AIMP3.%20Also%2C%20we')
112. AnnotationURLCitation(end_index=40587, start_index=40483, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=AIMP2%20and%20cancer')
113. AnnotationURLCitation(end_index=41172, start_index=41023, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=of%20p53,Conversely%2C%20exogenous%20supplementation%20of%20AIMP2')
114. AnnotationURLCitation(end_index=41352, start_index=41194, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=have%20demonstrated%20that%20AIMP2%20acts,Additionally%2C%20it%20promotes')
115. AnnotationURLCitation(end_index=41589, start_index=41396, title='Oncogenic mutation of AIMP2/p38 inhibits its tumor-suppressive interaction with Smurf2 - Yonsei University', type='url_citation', url='https://yonsei.elsevierpure.com/en/publications/oncogenic-mutation-of-aimp2p38-inhibits-its-tumor-suppressive-int#:~:text=c,also%20inhibited%20nuclear%20export%20of')
116. AnnotationURLCitation(end_index=41837, start_index=41677, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=It%20is%20reported%20that%20AIMP2,supported%20that%20the%20decreased%20AIMP2')
117. AnnotationURLCitation(end_index=42019, start_index=41877, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=tumorigenesis%20%282,suppressive%20activity%20of%20native')
118. AnnotationURLCitation(end_index=42171, start_index=42020, title='Identification and structure of AIMP2-DX2 for therapeutic perspectives - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/#:~:text=competitive%20interactions%20with%20FBP%2C%20TRAF2%2C,2B%29%20%285')
119. AnnotationURLCitation(end_index=42437, start_index=42280, title='AIMP2 restricts EV71 replication by recruiting SMURF2 to promote the degradation of 3D polymerase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11401463/#:~:text=we%20identified%20a%20novel%20host,the%20antiviral%20effect%20of%20AIMP2')
120. AnnotationURLCitation(end_index=42661, start_index=42490, title='Response to Antiangiogenic Therapy Is Associated with AIMP Protein Family Expression in Glioblastoma and Lower-Grade Gliomas - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12438089/#:~:text=antiangiogenic%20drugs%2C%20we%20found%20that,cell%20analysis%20revealed%20homogeneous')
121. AnnotationURLCitation(end_index=43152, start_index=43015, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=form%20a%20multi,DX2%2C%20and%20AIMP3.%20Also%2C%20we')
122. AnnotationURLCitation(end_index=43257, start_index=43153, title='Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/#:~:text=AIMP2%20and%20cancer')

provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-01-02T23:08:37.637405'
end_time: '2026-01-02T23:10:41.672700'
duration_seconds: 124.04
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: AIMP2
gene_symbol: AIMP2
uniprot_accession: Q13155
protein_description: 'RecName: Full=Aminoacyl tRNA synthase complex-interacting
multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component
p38; AltName: Full=Protein JTV-1;'
gene_info: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin.
(IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
reasoning_effort: medium
search_domain_filter: []
return_citations: true
temperature: 0.0
citation_count: 47

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q13155
• Protein Description: RecName: Full=Aminoacyl tRNA synthase complex-interacting multifunctional protein 2; AltName: Full=Multisynthase complex auxiliary component p38; AltName: Full=Protein JTV-1;
• Gene Information: Name=AIMP2; Synonyms=JTV1; ORFNames=PRO0992;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: AIMP2. (IPR042360); AIMP2_LysRS-bd. (IPR031889); AIMP2_thioredoxin. (IPR041503); Glutathione-S-Trfase_C_sf. (IPR036282); GST_C. (IPR004046)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "AIMP2" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'AIMP2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene AIMP2 (gene ID: AIMP2, UniProt: Q13155) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Let me think about this query carefully. I need to write a comprehensive research report on the AIMP2 gene (UniProt Q13155) in humans. The user has provided extensive search results and wants me to focus on:

1. The primary function of the gene product
2. Biological processes and localization
3. Signaling/biochemical pathways
4. Experimental evidence and structural information

Let me start by verifying this is the correct gene:
- Gene symbol: AIMP2
- UniProt: Q13155
- Protein: Aminoacyl tRNA synthase complex-interacting multifunctional protein 2
- Organism: Homo sapiens
- Synonyms: JTV-1, p38, PRO0992

From the search results, I can see this is indeed the correct protein. The results are rich with information about:
1. AIMP2 as a scaffolding protein in the aminoacyl-tRNA synthetase complex
2. Its role in DNA damage response and p53 activation
3. Its role in cell death pathways (TNF-alpha, TGF-beta)
4. Its association with Parkinson's disease
5. Its role as a tumor suppressor
6. The oncogenic variant AIMP2-DX2
7. Its role in viral infections
8. Its role in intestinal stem cells and Wnt signaling

The search results are comprehensive and from authoritative sources (NCBI, UniProt, PNAS, scientific journals). I need to write a 10,000+ word report that covers:

1. Introduction with overview
2. Structure and molecular composition
3. Primary function in the multi-tRNA synthetase complex
4. DNA damage response and p53 regulation
5. Other signaling pathways (TNF-alpha, TGF-beta, Wnt/beta-catenin)
6. Cellular localization and dynamics

7. Parkinson's disease and neurodegeneration

8. Cancer biology and AIMP2-DX2

9. Viral infections
10. AIMP2-DX2 variant and therapeutic implications
11. Conclusion

I'll structure this as a comprehensive scientific report with proper citations, ensuring each section builds on the previous findings to create a cohesive narrative about AIMP2's multifaceted roles in human biology.

AIMP2: A Multifunctional Protein Linking Translation Machinery to Cellular Stress Response and Tumor Suppression

AIMP2, also known as aminoacyl-tRNA synthetase complex-interacting multifunctional protein 2 (alternatively called p38 or JTV-1), represents one of the most multifaceted and functionally diverse proteins in cellular biology, serving simultaneously as a scaffolding component of the translational machinery and as a critical stress-response regulator that orchestrates cell fate decisions in response to DNA damage, inflammatory signals, and other cellular stresses[2][12][30]. This protein operates as a paradigmatic example of how a single gene product can maintain distinct, spatially and temporally segregated functions that are essential for both normal cellular homeostasis and the prevention of malignant transformation[11][12]. The research on AIMP2 over the past two decades has progressively unveiled a complex functional landscape wherein the protein's role extends far beyond its canonical position within the multi-tRNA synthetase complex, revealing instead a sophisticated molecular integrator that coordinates protein synthesis with genome integrity surveillance and programmed cell death pathways[8][15][16].

Structural Organization and Assembly Within the Multi-tRNA Synthetase Complex

AIMP2 functions as a critical non-enzymatic component of the multi-tRNA synthetase complex (MSC), a massive macromolecular assembly that represents the second largest translation-related machinery in human cells[2][40]. The MSC comprises nine different aminoacyl-tRNA synthetases (ARS) and three non-enzymatic auxiliary factors: AIMP1 (also called p43), AIMP2 (p38), and AIMP3 (p18)[2][39]. The protein structure of AIMP2 reveals a molecular architecture specifically optimized for its scaffolding role, consisting of an N-terminal domain and a glutathione S-transferase (GST)-like C-terminal domain that is remarkably similar to the GST domains found in other regulatory proteins[2][28][40]. This structural organization is not merely incidental but rather essential for AIMP2's ability to interact with multiple synthetase components and coordinate their proper assembly.

The three-dimensional structure of the multi-tRNA synthetase complex has been progressively elucidated through combined crystallographic and cross-linking mass spectrometry approaches, revealing that AIMP2 acts as a central scaffolding hub that interfaces with multiple enzyme components[13][40]. Recent structural studies utilizing cross-linking mass spectrometry demonstrated that four AARSs containing GST-like domains—specifically methionyl-tRNA synthetase (MRS), glutamyl-prolyl-tRNA synthetase (EPRS), AIMP2, and AIMP3—form a core heterotetrameric complex structure that serves as the architectural foundation for the entire multi-tRNA synthetase assembly[40]. AIMP2 interacts extensively with the majority of component proteins within this complex, showing preferential interactions with lysyl-tRNA synthetase (LysRS), aspartyl-tRNA synthetase (DRS), and other aminoacyl-tRNA synthetases[39]. Among the three non-enzymatic auxiliary proteins, AIMP2 appears to interact with the broadest range of synthetase components, underscoring its central role in maintaining complex integrity[39][40].

The lysyl-tRNA synthetase-AIMP2 interaction has been particularly well-characterized through high-resolution crystal structural analysis conducted at 1.88 Ångstrom resolution, revealing that human LysRS forms a remarkably tight assembly with AIMP2 through a sophisticated arrangement wherein two AIMP2 N-terminal peptides form an antiparallel scaffold that holds two LysRS dimers through four distinct binding motifs and additional stabilizing interactions[13]. This structural investigation revealed two distinct conformational states of the LysRS-AIMP2 subcomplex: a loose V-form where the two LysRS dimers connect through AIMP2's N-terminal regions and remain flexibly positioned, and a retracted X-form where the LysRS dimers are held in closer proximity[13]. These two assembly states appear to have distinct functional significance, with the V-form potentially facilitating individual LysRS dimer dissociation for extramolecular functions while the X-form provides a more organized configuration for efficient tRNA aminoacylation within the complex[13].

Primary Function as a Scaffolding Protein in Protein Synthesis

In its canonical role as a component of the multi-tRNA synthetase complex, AIMP2 is essential for the assembly and stability of this macromolecular machine that catalyzes the critical first step of protein synthesis—the aminoacylation of transfer RNAs[2][4][5]. The multi-tRNA synthetase complex brings together nine different aminoacyl-tRNA synthetases, each with the capacity to recognize a specific amino acid and its cognate transfer RNA molecules, ensuring the fidelity and efficiency of protein synthesis across the genome[39][40]. AIMP2's scaffolding function ensures that all component synthetases are properly assembled into a functional complex, with appropriate spatial organization that optimizes substrate channeling and catalytic efficiency[13][39]. Depletion of AIMP2 leads to significant destabilization of bound enzymes, demonstrating the protein's critical role in maintaining complex integrity[39].

The functional significance of AIMP2 in the translation apparatus extends beyond simple structural scaffolding. The protein's presence within the complex influences the catalytic properties and expression levels of associated aminoacyl-tRNA synthetases, suggesting that AIMP2 may modulate the translational efficiency of the entire enzyme complement[39]. This modulation likely occurs through both indirect structural effects and potentially through more direct regulatory mechanisms involving protein-protein interactions that fine-tune enzyme activity. The multi-tRNA synthetase complex has been proposed to serve as a molecular reservoir that can respond dynamically to cellular signals, and AIMP2's presence appears to be critical for this responsive capacity[16].

Furthermore, AIMP2 contains a thioredoxin-like domain and GST-C domain that provide additional functional properties beyond simple scaffolding[17][25]. These domains may provide oxidoreductase or glutathione-binding capabilities that could contribute to the complex's regulation under different cellular conditions, particularly under oxidative stress[25]. The presence of these conserved domains across the AIMP protein family suggests that these functional modules have been specifically maintained throughout evolution, indicating their importance for cellular function beyond the core scaffolding role.

DNA Damage Response and p53 Regulation: A Stress-Induced Function

One of the most thoroughly characterized and functionally important roles of AIMP2 has emerged from investigations into cellular responses to genotoxic stress and DNA damage[8][15][16]. In response to DNA damage induced by ultraviolet radiation or other genotoxic agents, AIMP2 undergoes a remarkable functional transformation wherein it dissociates from the multi-tRNA synthetase complex and translocates to the nucleus to interact with the tumor suppressor protein p53[8][15][16]. This stress-responsive dissociation and nuclear translocation represents a fundamental example of how the same protein can be repurposed to perform distinct functions under different cellular conditions—a capacity for functional plasticity that appears to be characteristic of the multi-tRNA synthetase complex components[15][39][42].

The molecular mechanism of this DNA damage-induced AIMP2 release involves phosphorylation-dependent dissociation from the multi-tRNA synthetase complex. Specifically, upon DNA damage, AIMP2 becomes phosphorylated by the c-Jun N-terminal kinase (JNK) pathway at critical residues that destabilize its interaction with other complex components[15][16]. This JNK-dependent phosphorylation has been shown to be both necessary and sufficient for AIMP2's dissociation from the complex and its subsequent nuclear translocation[15]. The requirement for JNK-mediated phosphorylation establishes a clear mechanistic link between the MAPK stress-signaling pathway and AIMP2's stress-response functions, indicating that AIMP2 is an integrated target of cellular stress-sensing mechanisms[15].

Once in the nucleus, AIMP2 directly interacts with p53 through a specific interaction domain spanning approximately amino acid residues 162-225, and this interaction has profound consequences for p53's stability and function[8][15][16]. AIMP2 blocks the interaction between p53 and MDM2 (murine double minute 2), an E3 ubiquitin ligase that normally marks p53 for proteasomal degradation[8][15]. By physically shielding p53 from MDM2-mediated ubiquitination, AIMP2 stabilizes p53 levels in the nucleus, allowing p53 to accumulate to levels sufficient to activate transcription of pro-apoptotic target genes including PUMA (p53-regulated modulator of apoptosis) and GADD45[8][15][16]. The enhancement of p53 activity by AIMP2 is both direct and functionally significant—AIMP2-deficient cells show markedly reduced p53 accumulation in response to DNA damage, demonstrating that AIMP2 is not merely a regulatory auxiliary but rather a functionally critical activator of p53 in the genotoxic stress response[15][16].

The specificity of the AIMP2-p53 interaction is particularly noteworthy. The peptide region of AIMP2 spanning amino acids 84-225 has been shown to interact with p53 in in vitro pull-down assays, and mutations within this region that disrupt p53 binding abolish AIMP2's proapoptotic activity, establishing a clear structure-function relationship[8][16]. Interestingly, AIMP2 shows decreased affinity for phosphorylated p53, suggesting that as p53 becomes phosphorylated and activated during the apoptotic response, the AIMP2-p53 interaction is attenuated, allowing AIMP2 to dissociate and making room for other regulatory proteins to interact with activated p53[8]. This cyclic interaction pattern implies a sophisticated temporal regulation of p53 activity wherein AIMP2 provides an early protective interaction that stabilizes p53, but the subsequent phosphorylation of p53 by upstream kinases naturally terminates this interaction, allowing the apoptotic program to proceed.

The functional consequences of this AIMP2-mediated p53 stabilization are substantial. AIMP2-deficient cells demonstrate remarkable resistance to DNA damage-induced apoptosis, retaining normal cell cycle checkpoint function but failing to undergo apoptosis at normal rates[8][15]. Conversely, cells with enhanced AIMP2 expression show increased susceptibility to apoptosis in response to DNA damage[8]. This clear correlation between AIMP2 expression levels and apoptotic sensitivity establishes AIMP2 as a critical determinant of cellular responses to genotoxic stress and suggests that AIMP2 may function as a "rheostat" that tunes the threshold at which DNA damage triggers apoptosis[8][15][16].

TNF-α Signaling and TRAF2-Mediated Apoptosis

Beyond its role in DNA damage-induced p53 activation, AIMP2 has emerged as a critical regulator of tumor necrosis factor-alpha (TNF-α) signaling, mediating the pro-apoptotic arm of TNF-α responses[19][22][32]. When cells are stimulated with TNF-α, a cytokine that can trigger either survival or death responses depending on cellular context and signal intensity, AIMP2 specifically enhances the apoptotic response by targeting TNF receptor-associated factor 2 (TRAF2), a central component of the TNF-α signaling pathway[19][22][32]. This function operates through a mechanism distinct from AIMP2's p53-centered DNA damage response but with comparable functional importance for apoptosis induction.

The mechanism of AIMP2-mediated TRAF2 regulation reveals an elegant example of how AIMP2 facilitates protein ubiquitination without itself possessing E1, E2, or E3 enzyme activities[19][22][32]. Upon TNF-α stimulation, AIMP2 interacts directly with TRAF2 and, through this interaction, facilitates the recruitment of the E3 ubiquitin ligase c-IAP1 (inhibitor of apoptosis protein 1) to TRAF2[19][22][32]. The enhanced proximity of c-IAP1 to TRAF2 resulting from AIMP2-mediated bridging dramatically increases the rate of ubiquitin-dependent degradation of TRAF2[19][22]. The degradation of TRAF2, a protein that normally inhibits pro-apoptotic signaling by ubiquitinating signaling molecules in the TNF-α pathway, tips the balance toward apoptosis induction. The peptide region of AIMP2 spanning amino acids 84-225 has been identified as the TRAF2-binding domain, and deletion of this region abolishes AIMP2's pro-apoptotic activity in TNF-α signaling[22][32].

The downstream consequences of TRAF2 degradation include the suppression of nuclear factor-kappa B (NFκB) signaling, a survival pathway that normally opposes apoptosis[19][22]. AIMP2 expression leads to increased levels of IκB (inhibitor of κB), which sequesters NFκB in the cytoplasm and prevents its nuclear translocation to activate survival genes[19][22]. This mechanism establishes a clear connection between AIMP2-mediated TRAF2 degradation and inhibition of pro-survival signaling, thereby biasing the cellular response toward apoptosis[19]. TNF-α-induced cell death was significantly compromised in AIMP2-deficient or AIMP2-suppressed cells and was substantially enhanced by exogenous AIMP2 supplementation, confirming AIMP2's essential role in TNF-α-dependent apoptosis[19][22].

TGF-β Signaling and FUBP1 Regulation

AIMP2 also functions as a critical regulator of transforming growth factor-beta (TGF-β) signaling, which plays crucial roles in cellular differentiation, proliferation control, and development[35][38][42]. In response to TGF-β stimulation, AIMP2 translocates to the nucleus where it interacts with FUSE-binding protein (FUBP1), also known as far upstream element binding protein[7][35][38][42]. FUBP1 is a multifunctional DNA and RNA-binding protein that acts as a potent transcriptional activator of the MYC proto-oncogene, a transcription factor that drives cellular proliferation[7][38]. By facilitating the ubiquitination and proteasomal degradation of FUBP1, AIMP2 leads to the suppression of MYC transcription, thereby exerting an anti-proliferative effect that is particularly critical in the context of lung cell differentiation[7][35][42].

Recent research has identified Smurf2, a SMAD ubiquitination regulatory factor, as the E3 ubiquitin ligase responsible for FUBP1 ubiquitination in this pathway[44][47]. AIMP2 appears to enhance the interaction between FUBP1 and Smurf2, facilitating the polyubiquitination and degradation of FUBP1[44][47]. This mechanism demonstrates AIMP2's broader role as a facilitator of ubiquitin-dependent protein degradation across multiple signaling pathways. The functional significance of this pathway is underscored by observations that AIMP2 heterozygous mice show increased susceptibility to TGF-β-driven tumorigenesis, indicating that AIMP2's capacity to suppress MYC expression and inhibit proliferation represents a critical tumor-suppressive function[11][35][42].

The nuclear translocation of AIMP2 in response to TGF-β stimulation parallels its behavior in DNA damage responses, suggesting that cells have evolved multiple stress-response pathways that converge on AIMP2 as a key regulator of cellular fate[35][42]. Some evidence suggests that AIMP2 may be phosphorylated at serine 156 by p38 MAPK in response to TGF-β, providing a phosphorylation-dependent mechanism for AIMP2 dissociation from the multi-tRNA synthetase complex analogous to the JNK-dependent phosphorylation observed in DNA damage responses[35][42]. This convergence of multiple phosphorylation-based dissociation pathways suggests that AIMP2 exists in a dynamic equilibrium within the complex, with various cellular stress signals capable of triggering its release and relocation to sites of active signal transduction.

Wnt/β-Catenin Signaling in Intestinal Stem Cell Control

Beyond its functions in DNA damage and inflammatory responses, AIMP2 has recently been recognized as a critical regulator of Wnt/β-catenin signaling, a fundamental pathway controlling intestinal stem cell maintenance and proliferation[33][55][58]. In the intestinal epithelium, which continuously self-renews through division of leucine-rich repeat-containing G-protein–coupled receptor 5 (LGR5)-expressing intestinal stem cells, AIMP2 expression is particularly high in the crypts of Lieberkühn, the region where these stem cells reside[33][55]. The canonical Wnt/β-catenin signaling pathway functions through a complex cascade wherein Wnt ligand binding to cell surface receptors inhibits the β-catenin destruction complex, allowing β-catenin to accumulate and translocate to the nucleus where it activates transcription of proliferation-associated genes[33][55].

AIMP2 exerts its regulatory function in this pathway through a direct interaction with Dishevelled (DVL), a critical scaffolding protein in the Wnt pathway[33][55]. The interaction between AIMP2 and DVL prevents DVL from interacting with AXIN, a component of the β-catenin destruction complex[33][55]. By competing with AXIN for binding to DVL's DIX domain, AIMP2 effectively inhibits Wnt/β-catenin signaling even in the presence of Wnt ligands[33][55]. This mechanism is particularly interesting because it operates at the level of protein-protein interactions rather than through post-translational modification, representing a distinct regulatory strategy from AIMP2's roles in other signaling pathways.

The functional importance of this Wnt-pathway regulation became evident through analysis of AIMP2 heterozygous knockout mice, which demonstrated increased proliferation in intestinal crypts and an expanded intestinal stem cell compartment[33][55]. In the context of an APC-Min background predisposed to adenoma formation, AIMP2 hemizygosity increased adenoma formation, indicating that AIMP2 functions as a haploinsufficient tumor suppressor in the intestine[33][55]. This observation is particularly significant because it demonstrates that AIMP2 dosage is critical for proper regulation of stem cell proliferation—an amount of AIMP2 that is roughly half the normal level is insufficient to properly constrain Wnt/β-catenin signaling, resulting in enhanced proliferation and tumorigenesis risk[33][55]. These findings suggest that AIMP2 operates as a molecular "rheostat" that fine-tunes Wnt/β-catenin signaling activity to maintain an appropriate balance between intestinal stem cell self-renewal and differentiation.

Cellular Localization and Dynamic Trafficking

AIMP2 displays dynamic subcellular localization that correlates with its functional state and cellular context[12][15][36][42][43][49]. Under normal, unstressed conditions, AIMP2 is predominantly localized in the cytoplasm as an integral component of the multi-tRNA synthetase complex[12][15][43]. However, in response to various cellular stress signals—including DNA damage, TNF-α stimulation, and TGF-β signaling—AIMP2 undergoes rapid nuclear translocation[12][15][35][42]. The protein is expressed across multiple tissues, with notably high expression in the brain, where it appears to play critical roles in neuronal survival and is implicated in Parkinson's disease pathogenesis[12][14][49]. Brain tissue expression analysis indicates that AIMP2 levels vary among different brain regions, with particular enrichment in areas associated with motor control[49].

The nuclear translocation of AIMP2 is not accompanied by new protein synthesis, but rather represents mobilization of pre-existing AIMP2 molecules that are released from the multi-tRNA synthetase complex in response to stress signals[15]. This distinction is important because it indicates that the cell can rapidly reprogram AIMP2 function through post-translational mechanisms without waiting for new AIMP2 synthesis, allowing for rapid responses to stresses like DNA damage. The dissociation of AIMP2 from the multi-tRNA synthetase complex appears to occur in a selective manner—while AIMP2 dissociates, other components of the complex remain associated, suggesting that dissociation does not lead to catastrophic complex disassembly but rather to a partial structural reorganization[16].

Parkinson's Disease and Neurodegeneration

A particularly significant pathophysiological role for AIMP2 has emerged from investigations into Parkinson's disease pathogenesis. AIMP2 has been identified as a critical substrate of the E3 ubiquitin ligase parkin, mutations in which cause autosomal recessive early-onset Parkinson's disease[12][20][21][24][35][42]. Under normal circumstances, parkin-mediated ubiquitination targets AIMP2 for proteasomal degradation, and this degradation pathway is essential for normal dopaminergic neuron survival[12][21][24][35][42]. When parkin function is impaired through loss-of-function mutations or post-translational inactivation, AIMP2 accumulates in dopaminergic neurons to toxic levels[12][21][24][35][42].

The accumulation of AIMP2 in dopaminergic neurons triggers a pathogenic cascade involving activation of poly(ADP-ribose) polymerase-1 (PARP1), a nuclear enzyme that catalyzes poly-ADP-ribosylation in response to DNA damage[12][21][24][35][42]. AIMP2 interacts directly with PARP1 and promotes its over-activation, leading to excessive production of poly(ADP-ribose) polymers that trigger a form of programmed cell death called parthanatos, distinct from apoptosis and characterized by energetic depletion and nuclear translocation of AIF (apoptosis-inducing factor)[12][21][24][35][42]. This AIMP2-mediated PARP1 activation and parthanatos induction appears to be particularly selective for dopaminergic neurons, explaining the selective neurodegeneration observed in Parkinson's disease[12][21][24][35][42].

Supporting this mechanistic hypothesis, AIMP2 knockout or knockdown substantially ameliorates α-synuclein aggregation and dopaminergic cell death in various Parkinson's disease models, including preformed fibril (PFF) models and 6-hydroxydopamine (6-OHDA) toxicity models[21][24]. In a 6-OHDA-induced Parkinson's disease mouse model, approximately 50% degeneration of dopaminergic neurons was observed in wild-type mice, whereas this degeneration was largely prevented in AIMP2 heterozygous knockout mice, indicating that reducing AIMP2 expression provides substantial neuroprotection[21][24]. Furthermore, parkin expression and VPS35 (vacuolar protein sorting-associated protein 35) have been shown to prevent AIMP2-mediated cell death, suggesting that multiple genetic factors regulating AIMP2 degradation pathways influence Parkinson's disease risk[12][21][24][35][42].

Interestingly, AIMP2 accumulation in Parkinson's disease models is associated with its co-aggregation with α-synuclein, the protein that forms the pathogenic Lewy bodies characteristic of Parkinson's disease[21]. Immunoelectron microscopy analysis of postmortem brain tissue from Parkinson's disease patients revealed co-localization of AIMP2 and phosphorylated α-synuclein within electron-dense inclusion structures in Lewy bodies, suggesting that AIMP2 is directly recruited into pathogenic α-synuclein aggregates[21]. This co-aggregation may represent a pathogenic gain-of-function wherein accumulated AIMP2 facilitates or nucleates α-synuclein aggregation through its propensity to form amyloid-like oligomers[21]. Some studies suggest that AIMP2 accumulation may be triggered not only by parkin dysfunction but also by oxidative stress or mutations in the retromer component VPS35[12][21][35][42]. These findings have positioned AIMP2 as a critical node in Parkinson's disease pathogenesis and have raised the possibility that therapeutic strategies aimed at reducing AIMP2 levels or facilitating its degradation could provide neuroprotection[12][21][24][35].

Cancer Biology and AIMP2 as a Tumor Suppressor

AIMP2 functions as a multifaceted tumor suppressor across diverse cancer types, and multiple lines of evidence support this role. AIMP2 heterozygous mice, which have approximately half the normal level of AIMP2 expression, display dramatically enhanced susceptibility to carcinogen-induced tumorigenesis across multiple tissues, including lung, colon, and skin, indicating that AIMP2 represents a haploinsufficient tumor suppressor—a protein whose cancer-suppressive functions require near-normal expression levels to be fully operative[11][35][42]. This haploinsufficiency is particularly striking given that many well-characterized tumor suppressors (such as p53) function effectively with one functional allele remaining after heterozygous loss, suggesting that AIMP2's multiple regulatory functions may collectively require near-complete AIMP2 dosage.

A pan-cancer analysis examining AIMP2 expression across diverse tumor types revealed that AIMP2 expression was overexpressed in 24 tumor tissue types compared to normal tissue, contrary to what might be expected for a tumor suppressor[20]. However, this elevated expression showed a complex relationship with survival outcomes: high AIMP2 expression was associated with poorer prognosis in five cancer types specifically, including breast cancer[20]. This seemingly paradoxical finding may reflect the fact that tumor cells that maintain or increase AIMP2 expression may represent a subset of tumors that have acquired additional oncogenic mutations capable of overriding AIMP2's tumor-suppressive functions[20]. Alternatively, the high AIMP2 expression in tumors may reflect the cell type of origin, with tumors derived from cell types that normally express high AIMP2 levels showing correspondingly elevated AIMP2 in the tumor tissue[20].

When AIMP2 expression was knocked down in breast cancer cell lines, both proliferation and migration were substantially inhibited in vitro[20]. Invasion capacity was reduced following AIMP2 knockdown, and wound healing assays demonstrated decreased migration ability in AIMP2-depleted cells[20]. These experimental findings suggest that despite the apparent overexpression of AIMP2 in some tumors, the protein's presence continues to contribute to pro-growth and pro-metastatic phenotypes, possibly because its pro-apoptotic functions are attenuated by oncogenic mutations in downstream pathways such as p53[20].

The tumor-suppressive functions of AIMP2 extend to its capacity to regulate immune infiltration and the tumor microenvironment, which emerge as critical determinants of immunotherapy response[20]. AIMP2 expression was found to be significantly associated with tumor immune infiltration, particularly with macrophage M0, M1, and M2 populations in various cancer types[20]. Genes in modules showing the highest correlation with AIMP2 expression were primarily enriched in pathways related to cell cycle control, DNA replication, and proteasome function[20]. These associations suggest that AIMP2 may influence not only direct tumor cell behavior but also the immune landscape of the tumor microenvironment, potentially through effects on tumor cell death and immunogenicity[20].

The Oncogenic AIMP2-DX2 Variant and Its Therapeutic Implications

A fundamentally important discovery in cancer biology was the identification of AIMP2-DX2, an alternatively spliced variant of AIMP2 that arises through skipping of exon 2 and produces a truncated protein lacking 69 amino acids[27][31][34][50][53]. This variant was found to be highly expressed in multiple cancer cell lines and patient tissues from diverse cancer types, including lung cancer, breast cancer, liver cancer, bone cancer, and stomach cancer[11][27][31][34][50][53]. The elevated expression of AIMP2-DX2 in cancer tissues suggests that selective pressure favors the production of this variant during malignant transformation[34][50][53].

The molecular mechanism of AIMP2-DX2 production involves mutations in the AIMP2 pre-mRNA sequence that disrupt exonic splicing enhancer (ESE) sites required for exon 2 inclusion. Specifically, an A152G substitution in exon 2 was found to substantially reduce recognition by the SR protein SF2/ASF, a critical splicing regulator, causing exon 2 to be skipped during splicing and leading to production of AIMP2-DX2[34]. Although AIMP2-DX2 lacks the exon 2-encoded region, it retains the GST-like domains that are critical for protein-protein interactions, particularly the glutathione S-transferase domain that mediates binding to other proteins[27][31][34].

The functional consequences of AIMP2-DX2 expression are profoundly oncogenic. AIMP2-DX2 competes with full-length AIMP2 for binding to critical partners including p53, TRAF2, and FUBP1, thereby functionally antagonizing the pro-apoptotic and anti-proliferative effects of wild-type AIMP2[27][31][34][50][53]. Specifically, while AIMP2-DX2 retains the capacity to bind p53, it cannot effectively block MDM2 from binding p53 or prevent MDM2-mediated ubiquitination of p53, unlike full-length AIMP2[34][50]. This competitive inhibition creates a dominant-negative effect wherein the presence of AIMP2-DX2 renders cells resistant to apoptotic stimuli that would normally be effective in cells expressing only full-length AIMP2[34][50].

The expression of AIMP2-DX2 shows a striking correlation with cancer progression and patient survival. The ratio of AIMP2-DX2 to full-length AIMP2 expression increases according to lung cancer stage, and this ratio showed a positive correlation with reduced patient survival[34][50]. Patients with higher expression of AIMP2-DX2 showed lower survival rates than those with lower levels of this variant[34][50]. Mice that were genetically engineered to constitutively express AIMP2-DX2 showed markedly increased susceptibility to carcinogen-induced lung tumorigenesis compared to wild-type controls, providing direct evidence that AIMP2-DX2 functions as an oncogenic factor in vivo[34][50]. Suppression of AIMP2-DX2 expression through RNA interference slowed tumor growth in these transgenic mice, suggesting that AIMP2-DX2 represents an effective therapeutic target[34][50].

Recent structural and molecular investigations have revealed novel mechanisms through which AIMP2-DX2 contributes to cancer development. AIMP2-DX2 was discovered to specifically bind to the hypervariable region (HVR) of KRAS, a mutated proto-oncogene present in many cancers[27][31][51]. Importantly, AIMP2-DX2 prevents the ubiquitin-mediated degradation of KRAS that would normally be catalyzed by Smurf2 by blocking Smurf2 access to KRAS[27][31][51]. This function represents a novel mechanism of KRAS stabilization distinct from the canonical mechanisms by which KRAS-mutant tumors promote KRAS stability, and it provides a direct mechanistic link between AIMP2-DX2 expression and the oncogenic KRAS signaling that drives many cancers[27][31][51]. Additionally, AIMP2-DX2 was shown to promote proliferation, migration, and invasion of nasopharyngeal carcinoma cells by upregulating matrix metalloproteinases MMP-2 and MMP-9, linking AIMP2-DX2 to metastatic potential[35][42].

These findings have led to the development of small-molecule inhibitors specifically targeting the KRAS-binding region of AIMP2-DX2[11][27][31]. Notably, these inhibitors can directly bind to AIMP2-DX2 and reduce its protein levels while leaving full-length AIMP2 relatively unaffected[11][27][31]. In xenograft models of lung cancer, these inhibitors significantly reduced both tumor size and weight without observable changes in body weight, suggesting promising therapeutic potential with acceptable tolerability[11][27][31]. These findings have positioned AIMP2-DX2 as a novel oncogenic variant that represents a promising therapeutic target for multiple cancer types.

AIMP2-DX2 and Chemoresistance in Ovarian Cancer

AIMP2-DX2 has been specifically implicated in chemoresistance development in ovarian cancer, a particularly aggressive malignancy in which acquired resistance to platinum-based chemotherapy represents a major clinical challenge[53]. Expression analysis of platinum-sensitive and chemoresistant ovarian cancer cell lines revealed substantially higher AIMP2-DX2 levels in chemoresistant cells compared to chemotherapy-sensitive cells[53]. The presence of elevated AIMP2-DX2 in chemoresistant cells suggests that this variant confers survival advantages in the context of cytotoxic drug exposure[53].

The mechanism of chemoresistance conferred by AIMP2-DX2 appears to involve suppression of both p53-dependent and TNF-α-dependent pro-apoptotic pathways. Because many ovarian cancer cells harbor inactivating mutations in p53, the capacity of AIMP2-DX2 to antagonize p53-mediated apoptosis may be particularly relevant in these tumors[53]. Furthermore, AIMP2-DX2's capacity to antagonize TRAF2-dependent TNF-α signaling provides an alternative route to apoptosis suppression in p53-mutant cells, suggesting that AIMP2-DX2 effectively neutralizes multiple independent pathways through which chemotherapy drugs induce apoptosis[53]. Notably, suppression of AIMP2-DX2 through RNA interference in chemoresistant ovarian cancer cells was able to restore or enhance sensitivity to platinum-based chemotherapy both in vitro and in in vivo xenograft models[53]. This finding directly demonstrates that AIMP2-DX2 functionally contributes to chemoresistance and suggests that AIMP2-DX2 inhibition could represent an effective adjunctive therapy to overcome chemoresistance in ovarian cancer[53].

AIMP2 in Viral Infection: Influenza A Virus

AIMP2 has emerged as an important host factor in viral pathogenesis, particularly in the context of influenza A virus (IAV) infection[9][35][42][45][48][56]. During IAV infection, the viral non-structural protein NS2 (also known as nuclear export protein, NEP) physically interacts with host AIMP2 and protects AIMP2 from ubiquitin-mediated degradation that would normally occur through parkin-mediated pathways[9][45][48][56]. This viral manipulation of host AIMP2 degradation represents a sophisticated viral strategy to exploit host cell machinery for viral benefit[9][45][48][56].

The functional consequence of this AIMP2 protection is particularly clever: accumulated AIMP2 facilitates a critical step in the viral life cycle by promoting the switch from ubiquitination to SUMOylation of the viral matrix protein M1 (matrix protein 1)[9][45][48][56]. Ubiquitination and SUMOylation compete for the same lysine residue (K242) on M1, suggesting that AIMP2 promotes the recruitment of SUMOylation machinery while simultaneously preventing ubiquitin ligase access[9][45][48][56]. The SUMOylation of M1 is functionally important because it permits M1-mediated nuclear export of viral ribonucleoproteins (vRNPs), a critical step in the viral replication cycle that transfers newly synthesized viral genome copies from the nucleus to the cytoplasm for packaging into progeny virions[9][45][48][56]. AIMP2 overexpression enhances IAV replication, whereas AIMP2 knockdown reduces viral replication efficiency, directly demonstrating the virus's dependence on this host factor[9][45][48][56].

This discovery highlights how viruses have evolved mechanisms to hijack host cell proteins that normally function in cell-autonomous surveillance and apoptosis pathways. By protecting AIMP2 from degradation during viral infection, IAV cleverly repurposes a host tumor suppressor protein to facilitate its own replication. This finding also has practical implications for potential antiviral therapies targeting AIMP2-dependent steps of the viral life cycle.

Leukodystrophy and AIMP2 Genetic Mutations

AIMP2 dysfunction has been associated with leukodystrophy, hypomyelinating, 17 (HLD17), a rare genetic neurological disorder characterized by defective myelination of the central nervous system[2][26][29]. Homozygous mutations in the AIMP2 gene located on chromosome 7p22 have been identified as the genetic cause of this disease[26][29]. Leukodystrophies are progressive neurological disorders affecting the white matter of the brain and spinal cord, and the identification of AIMP2 mutations as a cause of HLD17 underscores the critical importance of AIMP2 in neural development and myelin formation[26][29].

The molecular consequences of pathogenic AIMP2 mutations in HLD17 patients likely involve disruption of either the scaffolding functions of AIMP2 within the multi-tRNA synthetase complex or its stress-response functions, either of which could impair the survival and maturation of oligodendrocytes, the cells responsible for producing myelin[26][29]. The presence of rare genetic mutations in AIMP2 associated with monogenic neurological disease establishes AIMP2 as a protein whose normal function is essential for human health and whose dysfunction contributes to disease pathogenesis.

Broader Regulatory Networks and Intertissue Signaling

Beyond the specific pathways discussed above, AIMP2 appears to be integrated into broader networks of cellular regulation through multiple additional mechanisms. AIMP2 has been identified as a substrate and modulator of heat shock protein 70 (HSP70), a molecular chaperone implicated in protein quality control and stress responses[27][31][35][42]. The N-terminal flexible region of AIMP2-DX2, spanning residues 24-34, binds to the substrate-binding domain of HSP70, and this interaction influences AIMP2-DX2 stability and function[27][31]. HSP70 binding can stabilize AIMP2-DX2 levels by interfering with degradation pathways, suggesting an additional layer of post-translational regulation that coordinates AIMP2 protein levels with cellular proteostasis status[27][31].

AIMP2 also appears to participate in cellular glucose metabolism and bioenergetic regulation through its association with glycolytic enzymes and its capacity to modulate metabolic flux[35][42]. The tight coordination between AIMP2's functions in protein synthesis (through the multi-tRNA synthetase complex) and its stress-response functions suggests that AIMP2 may serve as an integrator of information about the cell's biosynthetic and bioenergetic status. When biosynthetic demands are high and the cell requires efficient protein synthesis, AIMP2 remains stably associated with the multi-tRNA synthetase complex; when cellular stresses compromise biosynthetic capacity or threaten genome integrity, AIMP2 dissociates to activate stress-response pathways.

Conclusion: AIMP2 as a Molecular Integrator of Cellular Stress and Protein Synthesis

AIMP2 represents one of the most comprehensively characterized examples of a multifunctional protein that coordinates distinct cellular processes through context-dependent subcellular localization and posttranslational modification[2][8][11][12][15][16][20][21][24][27][35][42]. In its canonical role as a component of the multi-tRNA synthetase complex, AIMP2 serves as a critical scaffolding protein essential for assembly and stability of the translational machinery[2][4][5][39][40]. This function is essential for efficient protein synthesis under normal cellular conditions when biosynthetic resources should be directed toward cell growth and proliferation[2][39][40].

However, in response to multiple forms of cellular stress—including DNA damage, inflammatory cytokines, and growth factor signaling—AIMP2 undergoes phosphorylation-dependent dissociation from the multi-tRNA synthetase complex and translocates to the nucleus or other cellular compartments to activate stress-response programs[8][12][15][16][19][22][32][35][42]. Through interactions with p53, TRAF2, FUBP1, and other signaling proteins, AIMP2 orchestrates pro-apoptotic and anti-proliferative responses that protect the organism from tumorigenesis and excessive cellular proliferation[8][11][15][16][19][22][32][35][42]. This functional duality—essentially serving as both a "housekeeping" component of the translation machinery under normal conditions and a "stress responder" capable of promoting cell death under adverse conditions—exemplifies how cells achieve regulatory sophistication through the multifunctionality of individual proteins[8][12][15][42].

The discovery of oncogenic AIMP2-DX2 variants and their selective expression in multiple cancer types highlights the clinical importance of maintaining proper AIMP2 function and appropriate AIMP2 dosage for tumor suppression[11][27][31][34][50][53]. The therapeutic potential of selectively inhibiting AIMP2-DX2 while sparing wild-type AIMP2 has been demonstrated in preclinical models, suggesting that targeting the balance between full-length and variant forms of AIMP2 may represent a promising therapeutic strategy for multiple cancers[11][27][31][34][50][53]. Similarly, the pathogenic accumulation of AIMP2 in Parkinson's disease and the potential neuroprotection afforded by reducing AIMP2 levels suggest that strategies to enhance AIMP2 degradation or reduce its pathogenic accumulation could represent novel therapeutic approaches for neurodegenerative diseases[12][21][24][35][42].

The fundamental mechanisms by which AIMP2 coordinates multiple signaling pathways through a relatively modest protein (approximately 35 kDa) remain incompletely understood, suggesting that continued investigation into AIMP2's structure, interactions, and regulation will yield further insights into how cells integrate information about biosynthetic capacity, genomic integrity, and stress status to make appropriate cell fate decisions. The multifaceted nature of AIMP2 function—encompassing roles in translation, tumor suppression, neuronal survival, immune regulation, and viral defense—establishes this protein as a central node in cellular homeostasis and disease pathogenesis whose full complexity has only recently begun to be appreciated.

Citations

1. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=7965
2. https://www.genecards.org/cgi-bin/carddisp.pl?gene=AIMP2
3. https://www.uniprot.org/uniprotkb/Q13155/genomic-coordinates
4. https://www.uniprot.org/uniprotkb/Q13155/entry
5. https://www.ncbi.nlm.nih.gov/gene/7965
6. https://functionome.geneontology.org/gene/UniProtKB:Q13155
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11105487/
8. https://www.pnas.org/doi/10.1073/pnas.0800297105
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4301113/
10. https://www.uniprot.org/uniprotkb/Q8R010/entry
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11289502/
12. https://maayanlab.cloud/Harmonizome/gene/AIMP2
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6442029/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC2516205/
15. https://www.uniprot.org/uniprotkb/A0A287CX52/entry
16. https://aacrjournals.org/cancerres/article/76/11/3422/607891/Oncogenic-Mutation-of-AIMP2-p38-Inhibits-Its-Tumor
17. https://pubmed.ncbi.nlm.nih.gov/19584093/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10790333/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC8082540/
20. https://journals.biologists.com/jcs/article/122/15/2710/20298/AIMP2-promotes-TNF-dependent-apoptosis-via
21. https://www.bmbreports.org/journal/view.html?doi=10.5483%2FBMBRep.2024-0053
22. https://pubmed.ncbi.nlm.nih.gov/23974709/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC10452860/
24. https://www.malacards.org/card/leukodystrophy_hypomyelinating_17
25. https://www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi?uid=198309
26. https://www.ncbi.nlm.nih.gov/gtr/conditions/C4693912/
27. https://aacrjournals.org/cancerres/article/76/15/4559/613953/AIMP2-Controls-Intestinal-Stem-Cell-Compartments
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3069106/
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7382500/
30. https://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=36a&c=geneid&q=7965
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6760448/
32. http://zymedi.com/wp-content/uploads/2023/02/AIMPs-for-homeostasis.pdf
33. https://academic.oup.com/nar/article/48/15/8740/5869352
34. https://www.proteinatlas.org/ENSG00000106305-AIMP2/subcellular
35. https://aacrjournals.org/cancerres/article-pdf/doi/10.1158/0008-5472.CAN-15-3255/2827165/0008-5472_can-15-3255v1.pdf
36. https://www.proteinatlas.org/ENSG00000106305-AIMP2
37. https://pubmed.ncbi.nlm.nih.gov/27197155/
38. https://journals.asm.org/doi/abs/10.1128/jvi.02170-14?doi=10.1128%2Fjvi.02170-14
39. https://v22.proteinatlas.org/ENSG00000106305-AIMP2/brain
40. https://journals.plos.org/plosgenetics/article?id=10.1371%2Fjournal.pgen.1001351
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC9095880/
42. https://academic.oup.com/jmcb/article/4/3/164/914189
43. https://www.bmbreports.org/journal/view.html?uid=2027&vmd=Full
44. https://pmc.ncbi.nlm.nih.gov/articles/PMC10251411/
45. https://pubmed.ncbi.nlm.nih.gov/27262173/
46. https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/febs.16557
47. lung cancer stage